diclofenac has been researched along with celecoxib in 255 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (0.78) | 18.2507 |
| 2000's | 115 (45.10) | 29.6817 |
| 2010's | 107 (41.96) | 24.3611 |
| 2020's | 31 (12.16) | 2.80 |
| Authors | Studies |
|---|---|
| Brideau, C; Chan, CC; Charleson, S; Cromlish, W; Ethier, D; Evans, JF; Ford-Hutchinson, AW; Gauthier, JY; Gordon, R; Gresser, M; Guay, J; Kargman, S; Kennedy, B; Leblanc, Y; Léger, S; Mancini, J; O'Neill, GP; Ouellet, M; Percival, MD; Perrier, H; Prasit, P; Riendeau, D; Rodger, I; Wang, Z; Zamboni, R | 1 |
| Borst, P; de Haas, M; Kuil, A; Reid, G; van der Heijden, I; Wielinga, P; Wijnholds, J; Zelcer, N | 1 |
| Casini, A; Heine, A; Klebe, G; Kuhn, D; Scozzafava, A; Supuran, CT; Weber, A | 1 |
| Byvatov, E; Franke, L; Schneider, G; Schneider, P; Steinhilber, D; Werz, O | 1 |
| Chen, W; Jin, D; Liu, Q; Wang, J; Zhao, W; Zhu, X; Zou, J | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Dannhardt, G; Lindbom, L; Mattern, A; Scholz, M; Soehnlein, O; Ulbrich, HK | 1 |
| Ahmad, A; Ahuja, P; Ajmal, M; Alam, MM; Husain, A | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Abdel-Aziz, AA; Asiri, YA; ElTahir, KE | 1 |
| Honda, K; Izumi, T; Miyaji, Y; Nakayama, S; Okazaki, O; Okudaira, N; Shiosakai, K; Sugiyama, D; Suzuki, W; Takakusa, H; Watanabe, A | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Bhatti, R; Sharma, S; Singh, P | 1 |
| Bhatti, R; Kaur, M; Sharma, S; Singh, A; Singh, P | 1 |
| Boreddy, TS; Karpoormath, R; Palkar, MB; Rane, RA; Ronad, PM; Shaikh, MS; Singhai, AS; Veerapur, VP; Vishwanathswamy, AH | 1 |
| Bala, M; Bansal, S; Bhardwaj, V; Bhattacharya, S; Choudhary, S; Joseph, A; Singla, S; Suthar, SK | 1 |
| Banerjee, UC; Chakraborti, AK; Garg, SK; Goyal, R; Kumar, R; Meena, VS; Purohit, P; Seth, K | 1 |
| Dalby, KN; Kaoud, TS; Radwan, MF | 1 |
| Abdel-Aziz, AA; Abdel-Aziz, NI; Al-Suwaidan, IA; Alanazi, AM; Asiri, YA; El-Azab, AS; ElTahir, KE | 1 |
| Bhatti, R; Dhillon, P; Prasher, P; Singh, P | 1 |
| Anbhule, PV; Deshmukh, MB; Jamale, DK; Kolekar, GB; Patravale, AA; Undare, SS; Valekar, NJ; Vibhute, SS; Walekar, LS | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bhatti, R; Kaur, J; Kaur, S; Singh, G; Singh, P | 1 |
| Abdel-Aziz, AA; Abou-Zeid, LA; Ayyad, RR; El-Azab, AS; El-Sayed, MA; ElTahir, KEH | 1 |
| Abdel-Aziz, AA; Abou-Zeid, LA; Abu El-Enin, MA; El-Azab, AS; ElTahir, KE; Mohamed, MA | 1 |
| Lian, ZM; Liu, HY; Sheng, GH; Sun, J; Wang, S; Zhu, HL | 1 |
| Abdelall, EKA; Ali, WAM; Azouz, AA; Elshemy, HAH; Moawad, A; Safwat, NM | 1 |
| Bo, L; Chen, LZ; Liu, XH; Shi, JB; Sun, WW; Tang, WJ; Wang, JQ; Xiu, C; Zhou, HP | 1 |
| Bandresh, R; Shrivastava, SK; Srivastava, P; Tripathi, A; Tripathi, PN | 1 |
| Bernardino, AMR; Boechat, N; Dos Santos, MS; Faria, JV; Miguita, AGC; Vegi, PF | 1 |
| Abdel-Ghany, YS; Alaaeddine, R; Alaeddine, LM; Belal, ASF; El-Yazbi, AF; Hazzaa, A; Ismail, A; Moussa, G; Nassra, R | 1 |
| Abu-Serie, MM; AlFadly, ED; Bakkar, NZ; Bartolini, M; Belal, ASF; El-Yazbi, AF; Elkazaz, S; Elzahhar, PA; Ghareeb, DA; Iriepa, I; Janockova, J; Kobeissy, F; Moraleda, I; Rafeh, RW; Saudi, MNS; Shaltout, H; Soukup, O; Tramarin, A | 1 |
| Alaaeddine, R; Belal, ASF; Bruning, JB; Chua, BSK; El-Yazbi, AF; Elzahhar, PA; Frkic, RL; Ibrahim, TM; Ismail, A; Knape, T; Labib, H; Nassra, R; von Knethen, A; Wallner, N | 1 |
| Asif, M; Husain, A; Iqbal, MA; Iram, F; Khan, SA | 1 |
| Chung, HY; Hong, J; Ju, Z; Jung, JH; Kim, S; La Kim, E; Moon, HR; Su, M | 1 |
| Abid, OU; Ahmad, A; Ahmad, S; Ayaz, M; Hussain, F; Jan, MS; Mahmood, F; Rashid, U; Sadiq, A; Ullah, F | 1 |
| Bhatti, R; Kaur, J; Kaur, S; Kumari, P; Singh, P | 1 |
| Das, RD; Nivsarkar, M; Panchal, NB; Sagar, SR; Singh, DP; Sudarsanam, V; Vasu, KK | 1 |
| Neha, K; Wakode, S | 1 |
| Bhatti, R; Kaur, J; Kumari, P; Singh, P | 1 |
| Hamilton, LC; Warner, TD | 1 |
| Rodrigues, AD; Shou, M; Tang, C | 1 |
| Dedhiya, S; Kosinski, M; Osterhaus, JT; Ware, JE; Zhao, SZ | 1 |
| Agrawal, NM; Burr, AM; Eisen, G; Faich, G; Geis, GS; Goldstein, JL; Kent, JD; Lefkowith, JB; Makuch, R; Pincus, T; Silverstein, FE; Simon, LS; Stenson, WF; Verburg, KM; Whelton, A; Zhao, WW | 1 |
| Borenstein, D; Geis, GS; Lefkowith, JB; McKenna, F; Wallemark, C; Wendt, H | 1 |
| Tive, L | 1 |
| Browning, RA; Burgess, FW | 1 |
| Deray, G | 1 |
| Simon, LS | 1 |
| Alonso-López, R; Asomoza-Espinosa, R; Ferreira, SH; Gomes-Lopes, LD; Granados-Soto, V; Rufino, MO | 1 |
| Faich, G; Geis, GS; Lefkowith, JB; Maurath, C; Ridge, NJ; Verburg, KM; Whelton, A; White, WB | 1 |
| Burke, TA; Eisen, GM; Geis, GS; Goldstein, JL; Lefkowith, J; Peña, BM | 1 |
| Alonso-López, R; Asomoza-Espinosa, R; Castañeda-Hernández, G; Granados-Soto, V; Ortiz, MI; Torres-López, JE | 1 |
| McCormack, JP; Rangno, R | 1 |
| Geis, GS | 1 |
| Bianchi, M; Broggini, M | 1 |
| Dilger, K; Herrlinger, C; Klotz, U; Peters, J; Schweer, H; Seyberth, HW | 1 |
| Anderson, GM; Austin, PC; Juurlink, DN; Kopp, A; Laupacis, A; Mamdani, M; Naglie, G; Rochon, PA | 1 |
| Pfeifer, M | 1 |
| Calkin, AC; Dawood, T; Honisett, S; Komesaroff, PA; Sudhir, K; Williams, MR | 1 |
| Wright, JM | 1 |
| Castañeda-Hernández, G; Jaimes-Hernández, J; Medina-Peñaloza, RM; Oropeza-De La Madrid, E; Robles-San Román, M; Rosas-Ramos, R; Suárez-Otero, R | 1 |
| Chan, FK; Chung, SC; Hui, AJ; Hung, LC; Lee, KC; Leung, VK; Leung, WK; Suen, BY; Sung, JJ; To, KF; Wong, VW; Wu, JC | 1 |
| Graham, DY | 1 |
| Brenner, SS; Dilger, K; Herrlinger, C; Hofmann, U; Klotz, U; Marx, C; Mürdter, TE | 1 |
| Banerjee, R; Mohanakumar, KP; Sairam, K; Saravanan, KS | 1 |
| Lanas, A | 1 |
| Lems, WF; Nurmohamed, MT | 1 |
| Camici, G; Fiedler, M; Fratton, A; Gay, RE; Gay, S; Hellermann, JP; Hermann, M; Hurlimann, D; Lüscher, TF; Neidhart, M; Ruschitzka, F; Tanner, FC; Thiery, J | 1 |
| Oviedo, JA; Wolfe, MM | 1 |
| Harley, C; Wagner, S | 1 |
| Burian, M; Geisslinger, G | 1 |
| Devogelaer, JP; El Hajjaji, H; Manicourt, DH; Marcelis, A | 1 |
| Alausa, T; Bakris, GL; Folker, A; Hung, E; Izhar, M | 1 |
| Adami, S; Berenbaum, F; Bliddal, H; Gimona, A; Lee, A; Moore, A; Navarro, F; Poor, G; Reginster, JY; Robinson, J; Tannenbaum, H; Uebelhart, D; Zacher, J | 1 |
| Fricke, J; Jayawardene, S; Kellstein, D; Ott, D | 1 |
| Gotoh, T; Hoshino, T; Hwang, HJ; Mima, S; Mizushima, T; Mori, M; Takenaka, H; Tomisato, W; Tsuchiya, T; Tsutsumi, S | 1 |
| Cousin, M; Fiedorowicz-Fabrycy, IF; Gitton, X; Hawkey, CC; Hoexter, G; Nasonov, EL; Pikhlak, EG; Svoboda, P | 1 |
| Josten, C; Schmidt, CM; Tiemann, AH | 1 |
| Curran, MP; Lyseng-Williamson, KA | 1 |
| Chan, FK; Chung, SC; Hui, AJ; Hung, LC; Lee, YT; Leung, WK; Suen, BY; Sung, JJ; To, KF; Wong, VW; Wu, JC | 1 |
| Cryer, B | 1 |
| Bégaud, B; Boisseau, M; Moore, N; Umar, A; Upur, H; Yusup, A | 1 |
| Elfman, L; Johnsen, JI; Kogner, P; Lindskog, M; Orrego, A; Pettersen, I; Ponthan, F; Sveinbjörnsson, B | 1 |
| Dahlborg, R; Day, CA; Jacob, RF; Mason, RP; Walter, MF; Weng, Y | 1 |
| Cristofoletti, R; Fabricio, AS; Navarra, P; Souza, GE; Veiga, FH | 1 |
| Bühler, N; Camici, G; Chenevard, R; Gröne, HJ; Hermann, M; Kiss, E; Lüscher, TF; Ruschitzka, F; Shaw, S | 1 |
| Bogolepova, AE; Shakhmatova, EI | 1 |
| Berlin, JA; Chittams, J; Jaskowiak, J; Kimmel, SE; Kishel, L; Reilly, M; Strom, BL | 1 |
| Beaulieu, A; Dutta, D; Paster, Z; Sheldon, E; Sloan, VS; Yu, S | 1 |
| Brzosko, M; Kopsa, P; Kreisse, A; Lehmann, R; Litschig, S; Nischik, R; Sloan, VS; Thurston, H | 1 |
| Cho, YB; Han, CK; Joo, HJ; Jung, IH; Jung, K; Kim, JH; Kwak, WJ; Rhee, HI; Ryu, K | 1 |
| Hochberg, MC | 1 |
| Dutta, D; Fleischmann, R; Maldonado-Cocco, J; Sheldon, E; Sloan, VS; Yu, S | 1 |
| Alanoglu, Z; Ateş, Y; Orbey, BC; Türkçapar, AG | 1 |
| Meechan, J | 1 |
| Brune, K; Dormann, H; Hinz, B | 1 |
| Bishop-Bailey, D; Mitchell, JA; Vojnovic, I; Warner, TD | 1 |
| Burger, KJ; Fashola, TO; Krehan, G; Maeumbaed, R; Runge, H; Schell, E; Schlüter, P; Thurston, HJ; Trechsel, U; Wittenberg, RH | 1 |
| Alvarez-Soria, MA; Calvo, E; Egido, J; Hernández, M; Herrero-Beaumont, G; Largo, R; Sánchez-Pernaute, O; Santillana, J | 1 |
| Agrawal, NM; Andrade-Ortega, L; Bello, AE; Eisen, GM; Fort, JG; Goldstein, JL; Hanrahan, PS; Levy, RA; Singh, G; Stenson, WF; Triadafilopoulos, G; Wallemark, C | 1 |
| Baraliakos, X; Bohl-Bühler, MH; Braun, J; Feldtkeller, E; Zochling, J | 1 |
| Kandefer-Szerszeń, M; Majdan, M; Parada-Turska, J; Rzeski, W; Turski, WA | 1 |
| Capron, L; Lillo-Le Louët, A; Vautier, S; Wyplosz, B | 1 |
| Dieleman, JP; Mosis, G; Stricker, BCh; Sturkenboom, MC; van der Lei, J | 1 |
| Abrahan, L; Fakir-Bolte, C; Hwang, LJ; Lau, FL; Nadarajah, A | 1 |
| Abildstrom, SZ; Buch, P; Friberg, J; Gislason, GH; Jacobsen, S; Køber, L; Madsen, M; Rasmussen, JN; Rasmussen, S; Schramm, TK; Torp-Pedersen, C | 1 |
| Bijuklic, K; Colleselli, D; Kähler, CM; Mosheimer, BA | 1 |
| Castellsague, J; Maguire, A; Perez-Gutthann, S; Varas-Lorenzo, C | 1 |
| Lefkowith, JL; Verburg, KM; West, CR; Whelton, A | 1 |
| Henry, D; McGettigan, P | 1 |
| Cheon, YK; Cho, YD; Han, CH; Jang, JY; Kim, BS; Kim, JH; Kim, YS; Kwon, KH; Moon, JH; Shim, CS; Song, HJ | 1 |
| Abdalla, H; Buckley, E; Butler, M; Iohom, G; Larney, V; O'Brien, J; Shorten, GD; Szarvas, S | 1 |
| Marwali, MR; Mehta, JL | 1 |
| Brookhart, MA; Rassen, J; Schneeweiss, S; Solomon, DH; Wang, PS | 1 |
| Deray, G; Montalescot, G; Sibilia, J | 1 |
| Deray, G; Héloire, F; Valat, JP | 1 |
| Kong, SX; LeLorier, J; Rahme, E; Toubouti, Y; Watson, DJ | 1 |
| Chono, K; Funatsu, T; Hirata, T; Keto, Y; Kimoto, A; Sasamata, M | 1 |
| Bjørneboe, O; Dougados, M; Kvien, TK; Mikkelsen, K; Pham, T; Ravaud, P; Skomsvoll, JF; Tubach, F | 1 |
| Becker, TL; Gambero, A; Maróstica, M; Pedrazzoli, J | 1 |
| Dougados, M; Gitton, X; Moore, A; Yu, S | 1 |
| Alexandova, A; Kesiova, M; Kirkova, M; Todorov, S | 1 |
| Ashcroft, DM; Chen, LC | 1 |
| Jacobs, P; Loyd, M; Rublee, D | 1 |
| Kapelle, A; Klopsch, T; May, M; Regourd, E; Richter, M; Rudwaleit, M; Schwank, S; Sieper, J | 1 |
| Andriulli, A; Colaizzo, D; Dallapiccola, B; Di Mario, F; Franceschi, M; Grandone, E; Leandro, G; Niro, V; Pilotto, A; Scarcelli, C; Seripa, D | 1 |
| Davis, N; Fricke, J; Krammer, G; Yu, V | 1 |
| Cunha, DC; de-Sales, MP; Lyra, IL; Moura, RM; Queiroz, AF; Ribeiro, JK; Santos, EA | 1 |
| Klotz, U; Shi, S | 1 |
| Berger, M; Chan, FK; Niculescu, L; Peura, D; Wilcox, CM | 1 |
| Carlsson, T; Karlsson, JO; Petersen, A; Zetterberg, M | 1 |
| Lim, SS; Omar, SZ; Sockalingam, JK; Tan, PC | 1 |
| Dahlén, SE; Kumlin, M; Låstbom, L; Ryrfeldt, A; Selg, E | 1 |
| Fleischmann, R; Notter, M; Patel, NP; Reginster, JY; Sallstig, P; Tannenbaum, H | 1 |
| Emery, P; Koncz, T; Lowry, S; Pan, S | 1 |
| El Masry, MA; Gamie, Z; Macfarlane, RJ; Ng, BH; Schizas, C; Tsiridis, E; Velonis, S | 1 |
| Cavanaugh, PF; Chappell, DL; Dallob, AL; Flynn, ME; Hilliard, DA; Larson, PJ; Laterza, OF; Miller, J; Royalty, J; Schwartz, JI; Snyder, KM; Wagner, JA | 1 |
| Alvarez-Soria, MA; Calvo, E; Egido, J; Herrero-Beaumont, G; Largo, R; Moreno-Rubio, J; Santillana, J | 1 |
| Déciga-Campos, M; Granados-Soto, V; Medina-Santillan, R; Reyes-García, G | 1 |
| Brizuela, NY; Demurtas, SL; Meirovich, CI; Montrull, HL | 1 |
| Chang, JK; Ho, ML; Li, CJ; Liao, HJ; Wang, CK; Wang, GJ | 1 |
| Bampton, PA; Costa, M; De Fontgalland, D; Leach, PL; McLaughlin, K; Wattchow, DA | 1 |
| Baker, SJ; Boyce-Rustay, JM; Decker, MW; Honore, P; Kohnken, R; Simler, GH; Wensink, EJ; Zhong, C | 1 |
| Blau, L; Chung, MC; dos Santos, JL; Menegon, RF; Oliveira, EV; Peccinini, RG | 1 |
| El-Ghazaly, MA; El-Hazek, RM; Khayyal, MT; Nada, AS | 2 |
| Erdahl, WE; Gadd, ME; Graff, G; Kumar, J; Lal, N; Pfeiffer, DR; Yanni, JM | 1 |
| Arbogast, PG; Castellsague, J; Chung, CP; Daugherty, JR; García-Rodríguez, LA; Murray, KT; Ray, WA; Stein, CM; Varas-Lorenzo, C | 1 |
| Choy, EH; Gaugris, S; Jansen, JP; Nash, JT; Ostor, A; Stam, W | 1 |
| Sanyal, SN; Tanwar, L; Vaish, V | 1 |
| Elliott, WJ | 1 |
| Gögenur, I; Klein, M; Rosenberg, J | 1 |
| Cheng, TT; Cheung, R; Dong, Y; Feng, H; Lai, K; Lau, CS; Lin, HY; Parsons, B | 1 |
| Bakhle, YS; de Francischi, JN; dos Reis, WG; Ferreira-Alves, DL; Gassani, BC; Paiva-Lima, P; Rezende, RM | 1 |
| Kaur, J; Sanyal, SN; Tanwar, L; Vaish, V | 1 |
| Bernatsky, S; Rahme, E | 1 |
| Berger, MF; Chan, FK; Goldstein, JL; Lanas, A; Nguyen, H; Scheiman, J | 1 |
| Honjo, H; Iwamoto, K; Uwai, Y | 1 |
| Knotek, M; Ljubanovic, D; Mihovilovic, K | 1 |
| Bavry, AA; Cooper-Dehoff, RM; Gong, Y; Handberg, EM; Khaliq, A; Pepine, CJ | 1 |
| Berger, MF; Chan, FK; Goldstein, JL; Lanas, A; Nguyen, H; Peura, D; Sands, GH; Scheiman, JM; Wilcox, CM | 1 |
| Niebling, W | 1 |
| Akehurst, R; Brereton, N; Winn, B | 1 |
| Eberle, J; Fecker, LF; Rodust, PM; Stockfleth, E | 1 |
| Chan, FK; Goldstein, JL; Lanas, A; Li, C; Peura, DA; Sands, GH; Scheiman, JM; Wilcox, CM | 1 |
| Essex, MN; Kellner, HL; Li, C | 1 |
| Bannon, AW; Gauvin, DM; Gomez, EJ; Mikusa, J; Mills, CD; Nguyen, T; Salyers, AK; Tanga, FY; Zhong, C | 1 |
| Inoue, M; Irie, T; Kasahara, Y; Kasemura, T; Majima, T; Onodera, T; Takahashi, D | 1 |
| Baheti, KG; Ganorkar, SB; Shelke, RU; Yewale, SB | 1 |
| Daniels, S; Gibofsky, A; Manvelian, G | 1 |
| Harirforoosh, S; Pettit, WL; Wyatt, JE | 1 |
| Liebman, TN; Polsky, D; Stein, JA | 1 |
| Chandra, C; Chandy, SJ; Danda, D; Iliyas, MM; Mathew, AJ | 1 |
| Cannavà, C; Cardile, V; Cilurzo, F; Giannone, I; Puglisi, G; Stancanelli, R; Tommasini, S; Ventura, CA | 1 |
| Corigliano, A; De Sarro, G; Falcone, D; Galasso, O; Gallelli, L; Gasparini, G; Greco, M; Gulletta, E; Romualdi, P; Savino, R; Southworth, S; Terracciano, R; Ventura, V | 1 |
| Babu, PP; Kesanakurti, D; Kirti, PB; Sareddy, GR | 1 |
| Sifferlin, A | 1 |
| Beach, KJ; Brookhart, MA; Layton, JB; Le, HV; Poole, C; Schoenbach, VJ; Stürmer, T | 1 |
| Cooper, DL; Harirforoosh, S; Wood, RC; Wyatt, JE | 1 |
| Bullins, KW; Denham, JW; Hanley, AV; Hanley, GA; Harirforoosh, S; Panus, PC; Wood, RC; Wyatt, JE | 1 |
| Eghdami, K; Farshid, AA; Samadi, F; Tamaddonfard, E | 1 |
| Arimitsu, J; Hagihara, K; Hiyama, S; Iijima, H; Inoue, T; Kawai, S; Mukai, A; Nishida, T; Ogata, A; Shinzaki, S; Shiraishi, E; Takehara, T; Tsujii, M | 1 |
| Aserin, A; Cohen-Avrahami, M; Garti, N; Ottaviani, MF; Shames, AI | 1 |
| Akehurst, R; Brereton, N; Ekelund, M; Pennington, B | 1 |
| Fukazawa, H; Inoue, M; Kaneko, Y; Miyazaki, Y; Niki, M; Ohno, H; Tanabe, K; Umeyama, T; Urai, M | 1 |
| Hu, RW; Li, HY; Li, JS; Miao, XP; Ouyang, Q; Zhang, Y | 1 |
| Buttgereit, F; Spies, CM; Stemmler, E | 1 |
| Bannuru, RR; Kent, DM; McAlindon, TE; Schmid, CH; Vaysbrot, EE; Wong, JB | 1 |
| Bannon, AW; Joshi, SK; Zhu, CZ | 1 |
| Akhondzadeh, S; Arya, P; Emami, SA; Esfandbod, M; Kashani, L; Kaviani, A; Mohammadinejad, P; Najafi, M; Zeinoddini, A | 1 |
| Di Franco, M; Frati, L; Guarino, ML; Guzzo, MP; Massimi, I; Pulcinelli, FM; Temperilli, F; Valesini, G | 1 |
| Anstaett, P; Ferrari, S; Gasser, G; Pierroz, V | 1 |
| Denham, JW; Harirforoosh, S; Murrell, DE; Panus, PC; Rahmasari, Y | 1 |
| Balbontín-Ayala, F; Cañigral, A; Carlos, Fd; Cobo, T; Fernández-González, FJ; Fernández-Vázquez, JP; Gonzalo-Orden, JM; Sánchez-Lasheras, F; Vega, JA | 1 |
| Matteson, EL; Thongprayoon, C; Ungprasert, P | 1 |
| Hansen, SH; Skonberg, C; Syed, M | 1 |
| Mackenzie, LS; Patel, P; Perez-Diaz, N; Tang, L; Zloh, M | 1 |
| Kanbayashi, Y; Konishi, H | 1 |
| Essex, MN; Li, C; Park, PW; Walker, C | 1 |
| Eroksuz, H; Gul, HF; Gungor, H; Ilhan, N | 1 |
| Choi, KH; Chung, MW; Lee, HJ; Park, JH; Um, SY | 1 |
| Ghanghas, P; Jain, S; Rana, C; Sanyal, SN | 2 |
| Agrawal, R; Assaiya, A; Banerjee, T; Jain, N; Kumar, A; Manivannan, E; Mufti, I; Parmar, HS; Tiwari, S | 1 |
| Álvarez, MG; Baamonde, A; Cernuda-Cernuda, R; Fernández-García, MT; Folgueras, AR; García-Domínguez, M; González-Rodríguez, S; Hidalgo, A; Lastra, A; Menéndez, L | 1 |
| Kumar, KH; Lokanatha, V; Madhava, G; Raju, CN; Ramana, KV; Rani, AU; Rao, DS; Sudhana, SM | 1 |
| Liu, Z; Liu, ZL; Shen, XH; Tian, YZ; Xu, Y | 1 |
| Marin, A; Markotic, F; Puljak, L; Tugwell, P; Utrobicic, A; Vrdoljak, D | 1 |
| Bauk, L; Drmic, D; Klicek, R; Kokot, A; Luetic, K; Seiwerth, S; Sikiric, P; Stupnisek, M; Vcev, A; Vitaic, S | 1 |
| Wang, J | 1 |
| Breivik, H | 1 |
| Demougeot, C; Marie, C; Prati, C; Prigent-Tessier, A; Totoson, P; Tournier-Nappey, M; Verhoeven, F; Wendling, D | 1 |
| Radhakrishnan, J; Radhakrishnan, R; Yellepeddi, VK | 1 |
| Abdelwahab, S; Abdelzaher, WY; Ibrahim, MA; Rofaeil, RR | 1 |
| Chang, CH; Dong, YH; Hwang, JS; Toh, S; Wu, LC | 1 |
| Chang, CC; Chen, YR; Chi, NF; Chiou, HY; Hsieh, FI; Wu, HC | 1 |
| Eroksuz, H; Gungor, H; Ilhan, N | 1 |
| Hossy, BH; Miguel, NCO; Padua, TA; Pierre, MBR; Quiñones, OG; Ramos, MFS; Rosas, EC | 1 |
| Ashour, HM; Fahmy, SM; Khalil, MA; Labouta, IM; Nassra, RA; Tageldin, GN | 1 |
| Bi, J; Yu, C; Yu, X; Yu, Z; Zhao, L | 1 |
| Kao Yang, YH; Kubota, K; Lai, EC; Man, KKC; Park, BJ; Pratt, N; Roughead, EE; Setoguchi, S; Shin, JY; Wong, ICK | 1 |
| Amirjanova, VN; Antipova, OV; Babaeva, AR; Davtyan, VG; Davydova, AF; Filatova, EA; Ivanova, ON; Kalinina, NN; Karateev, AE; Kiseleva, NI; Knyazeva, LA; Kulikov, AI; Lila, AM; Masneva, LV; Mazurov, VI; Menshikova, LV; Nesmeyanova, OB; Obuhova, IV; Otteva, EN; Pogozheva, EY; Salnikova, TS; Shсhendrygin, IN; Volkorezova, AV; Yakupova, SP; Zonova, EV | 1 |
| Ashour, HM; Fahmy, SM; Ibrahim, TM; Khalil, MA; Labouta, IM; Nassra, RA; Tageldin, GN | 1 |
| Naserzadeh, P; Neshat, MR; Pourahmad, J; Salimi, A | 1 |
| Akram, S; Ali, SN; Ayub, A; Naz, N; Qayoom, A | 1 |
| Chen, H; Huang, H; Liang, G; Liu, J; Pan, B; Pan, J; Yang, W; Zeng, L | 1 |
| Hou, S; Huang, H; Liang, G; Liang, H; Liu, J; Luo, M; Pan, J; Yang, W; Zeng, L; Zhao, J | 1 |
| Fukami, Y; Hashimoto, A; Iwamoto, S; Kaneko, K; Komatsu, S; Kurahashi, S; Mishima, H; Murotani, K; Saito, T; Sano, T | 1 |
| Brown, MT; Carrino, JA; Fountaine, RJ; Guermazi, A; Hickman, A; Hochberg, MC; Nakajo, S; Pixton, G; Schnitzer, TJ; Verburg, KM; Viktrup, L; Walsh, DA; West, CR; White, A | 1 |
| Hooten, WM; Moman, RN | 1 |
| Ali, MM; Nissan, YM; Ragab, FAE; Salem, MA; Selim, AAMA | 1 |
| Abdel-Bary, A; El-Tahan, RA; Gowayed, MA | 1 |
| Abdelhady, SA; Abdelmawgoud, EM; Al-Shafie, TA; Ali, MA; El-Mas, MM; Yacout, DM | 1 |
| Aguirre-García, VA; Pérez-Luna, IRM; Vázquez-Fuentes, BR; Vega-Morales, D | 1 |
| Auletta, LL; de Almeida Macedo, E; de Campos, GC; Kummer, AM; Millan Fachi, M; Papaleo Rosim, M | 1 |
| Ding, X; Li, X; Lu, N; Wang, Y; Wu, Z | 1 |
| Cheng, Y; Huang, Y; Jiang, W; Zhang, Y | 1 |
| Hjemdahl, P; Stiller, CO | 1 |
| Batra, A; Cheung, WY; Gogia, A; Gupta, I; Gupta, N; Kumar, A; Pandey, RM; Pramanik, R; Prasad, CP; Santhosh, A; Sharma, A | 1 |
| Asparago, G; Cuozzo, F; Maffulli, N; Migliorini, F; Oliva, F | 1 |
| Kang, M; Kim, B; Kim, MG; Moon, SJ; Shin, N | 1 |
| Pedersen, L; Schmidt, M; Sørensen, HT | 1 |
| Gorenflo, M; Saur, P; van den Anker, JN; van Dyk, M; Welzel, T; Ziesenitz, VC | 1 |
| Adema, GJ; Ansems, M; Raaijmakers, TK; Scheffer, GJ; van den Bijgaart, RJE | 1 |
| Abdelhady, SA; Ali, MA; El-Mas, MM; Elblehi, SS; Kandil, LS; Yacout, DM | 1 |
| Abdelkhalek, AS; Elbaramawi, SS; Kothayer, H; Rezq, S; Romero, DG | 1 |
| Adachi, K; Murayama, N; Nakano, H; Ohyama, K; Saito, Y; Sato, T; Shimizu, M; Tanaka, Y; Yamazaki, H | 1 |
| Blake, L; Carvalho, B; Carver, AL; Desai, N; Murdoch, I; O'Carroll, JE; Onwochei, DN; Sultan, P | 1 |
| Abdelkhalek, AS; El-Sabbagh, OI; Kothayer, H; Orabi, KY; Rezq, S; Romero, DG | 1 |
| Abdelhady, SA; Ali, MA; El-Mas, MM; Essawy, MM; Kandil, LS; Yacout, DM | 1 |
31 review(s) available for diclofenac and celecoxib
| Article | Year |
|---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Recently reported biological activities of pyrazole compounds.
Topics: Analgesics; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antifungal Agents; Antineoplastic Agents; Antiviral Agents; Humans; Pyrazoles | 2017 |
Insights into the chemistry and therapeutic potential of furanones: A versatile pharmacophore.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antifungal Agents; Antineoplastic Agents; Antiviral Agents; Humans; Molecular Structure | 2019 |
Contemporary advances of cyclic molecules proposed for inflammation.
Topics: Animals; Anti-Inflammatory Agents; Dose-Response Relationship, Drug; Humans; Inflammation; Molecular Structure; Structure-Activity Relationship | 2021 |
Celecoxib clinical profile.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Humans; Ibuprofen; In Vitro Techniques; Isoenzymes; Kidney Diseases; Membrane Proteins; Middle Aged; Naproxen; Osteoarthritis; Pain; Peptic Ulcer; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Treatment Outcome | 2000 |
COX-2 inhibitors. Are they nonsteroidal anti-inflammatory drugs with a better safety profile?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Forecasting; Humans; Ibuprofen; Isoenzymes; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides | 2001 |
The double-edged sword of COX-2 selective NSAIDs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Diclofenac; Gastrointestinal Diseases; Humans; Pyrazoles; Sulfonamides | 2002 |
Gastroprotection by coxibs: what do the Celecoxib Long-Term Arthritis Safety Study and the Vioxx Gastrointestinal Outcomes Research Trial tell us?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Enzyme Inhibitors; Gastrointestinal Hemorrhage; Humans; Lactones; Misoprostol; Omeprazole; Osteoarthritis; Proton Pump Inhibitors; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Sulfones | 2003 |
[Clinical pharmacology of the selective COX-2 inhibitors].
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Clinical Trials, Phase III as Topic; Cyclooxygenase Inhibitors; Diclofenac; Humans; Isoxazoles; Lactones; Naproxen; Osteoarthritis; Pain; Pain, Postoperative; Placebos; Pyrazoles; Sulfonamides; Sulfones | 2003 |
COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cost-Benefit Analysis; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Etoricoxib; Humans; Isoxazoles; Lactones; Membrane Proteins; Organic Chemicals; Osteoarthritis; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Rheumatology; Sulfonamides; Sulfones; Treatment Outcome | 2005 |
Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Humans; Lactones; Naproxen; Pyrazoles; Risk; Sulfonamides; Sulfones | 2006 |
COX-2 inhibitors and cardiovascular risk. Inferences based on biology and clinical studies.
Topics: Animals; Blood Platelets; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Labeling; Endothelium, Vascular; Epoprostenol; Humans; Lactones; Platelet Aggregation; Product Surveillance, Postmarketing; Pyrazoles; Randomized Controlled Trials as Topic; Risk Assessment; Sulfonamides; Sulfones; Thromboxane A2 | 2006 |
[What do we know about the cardiovascular toxicity of the NSAIDs?].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celecoxib; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Follow-Up Studies; Humans; Isoxazoles; Lactones; Meta-Analysis as Topic; Middle Aged; Naproxen; Pyrazoles; Randomized Controlled Trials as Topic; Risk Factors; Sulfonamides; Sulfones; Thrombosis; Time Factors | 2006 |
[Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Diclofenac; Edema; Heart Failure; Humans; Hypertension; Isoxazoles; Lactones; Meta-Analysis as Topic; Middle Aged; Odds Ratio; Placebos; Prospective Studies; Pyrazoles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Sulfonamides; Sulfones; Thrombosis; Time Factors | 2006 |
Evaluation of the patient acceptable symptom state in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis.
Topics: Aged; Celecoxib; Diclofenac; Double-Blind Method; Female; Humans; Male; Middle Aged; Osteoarthritis; Pain Measurement; Patient Satisfaction; Pyrazoles; Sulfonamides | 2007 |
Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Etoricoxib; Humans; Isoxazoles; Lactones; Models, Statistical; Myocardial Infarction; Naproxen; Odds Ratio; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Risk; Risk Factors; Sulfonamides; Sulfones | 2007 |
Clinical use and pharmacological properties of selective COX-2 inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Monitoring; Etoricoxib; Humans; Osteoarthritis; Pain; Pyrazoles; Pyridines; Sulfonamides; Sulfones | 2008 |
Pharmacological treatment of heterotopic ossification following hip and acetabular surgery.
Topics: Acetabulum; Anti-Inflammatory Agents, Non-Steroidal; Arthroplasty, Replacement, Hip; Celecoxib; Diclofenac; Humans; Indomethacin; Naproxen; Ossification, Heterotopic; Postoperative Complications; Pyrazoles; Sulfonamides | 2008 |
Do the blood pressure effects of nonsteroidal antiinflammatory drugs influence cardiovascular morbidity and mortality?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Humans; Hypertension; Isoxazoles; Lactones; Pyrazoles; Pyridines; Risk; Risk Factors; Sulfonamides; Sulfones | 2010 |
Pharmacogenetics of nonsteroidal anti-inflammatory drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Aspirin; Celecoxib; Cytochrome P-450 CYP2C9; Diclofenac; Humans; Ibuprofen; Indomethacin; Pharmacogenetics; Pyrazoles; Sulfonamides | 2012 |
Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Colitis, Ulcerative; Crohn Disease; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Humans; Isoxazoles; Lactones; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Safety-Based Drug Withdrawals; Sulfonamides; Sulfones | 2014 |
Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis.
Topics: Acetaminophen; Adrenal Cortex Hormones; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Humans; Hyaluronic Acid; Ibuprofen; Injections, Intra-Articular; Naproxen; Osteoarthritis, Knee; Pain; Pyrazoles; Sulfonamides; Treatment Outcome; Viscosupplements | 2015 |
Experimental evidence of pharmacological management of anchorage in Orthodontics: A systematic review.
Topics: Acetylcysteine; Animals; Anti-Inflammatory Agents; Antioxidants; Bone Remodeling; Celecoxib; Clodronic Acid; Diclofenac; Diphosphonates; Humans; Imidazoles; Interferon-gamma; Isoxazoles; Lactones; Mice; Orthodontic Anchorage Procedures; Osteoclasts; Osteoprotegerin; Pamidronate; Rats; Resveratrol; Stilbenes; Sulfones; Tooth Mobility; Tooth Movement Techniques; Zoledronic Acid | 2015 |
Nonaspirin Nonsteroidal Anti-Inflammatory Drugs and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Observational Studies.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cerebral Hemorrhage; Diclofenac; Humans; Ibuprofen; Incidence; Indomethacin; Lactones; Meloxicam; Naproxen; Observational Studies as Topic; Odds Ratio; Piroxicam; Proportional Hazards Models; Stroke; Sulfones; Thiazines; Thiazoles | 2016 |
Celecoxib for osteoarthritis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Diclofenac; Female; Humans; Male; Middle Aged; Naproxen; Osteoarthritis, Hip; Osteoarthritis, Knee; Pain Measurement; Placebos; Quality of Life; Randomized Controlled Trials as Topic | 2017 |
Meta-analysis Comparing Celecoxib with Diclofenac Sodium in Patients with Knee Osteoarthritis.
Topics: Celecoxib; Diclofenac; Humans; Osteoarthritis, Knee; Pain; Treatment Outcome | 2021 |
Efficacy of ultramicronised diclofenac in patients with osteoarthritis - systematic review with network meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Diclofenac; Humans; Network Meta-Analysis; Osteoarthritis; Pain; Randomized Controlled Trials as Topic; Treatment Outcome | 2021 |
Lessons from 20 years with COX-2 inhibitors: Importance of dose-response considerations and fair play in comparative trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Fibrinolytic Agents; Humans; Ibuprofen; Lactones; Naproxen; Prostaglandins; Prostaglandins I; Sulfones; Thromboxanes | 2022 |
Efficacy and Safety of NSAIDs in Infants: A Comprehensive Review of the Literature of the Past 20 Years.
Topics: Adolescent; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Child; Chronic Disease; Diclofenac; Flurbiprofen; Humans; Ibuprofen; Infant; Ketoprofen; Ketorolac; Meloxicam; Naproxen; Niflumic Acid; Pain | 2022 |
Comparison of different nonsteroidal anti-inflammatory drugs for cesarean section: a systematic review and network meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cesarean Section; Diclofenac; Female; Humans; Indomethacin; Ketorolac; Network Meta-Analysis; Pain; Pregnancy | 2023 |
58 trial(s) available for diclofenac and celecoxib
| Article | Year |
|---|---|
Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Celecoxib; Diclofenac; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Misoprostol; Pyrazoles; Quality of Life; Severity of Illness Index; Sickness Impact Profile; Sulfonamides; Surveys and Questionnaires; Treatment Outcome | 2000 |
Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
Topics: Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Female; Gastrointestinal Diseases; Humans; Ibuprofen; Isoenzymes; Male; Membrane Proteins; Middle Aged; Osteoarthritis; Peptic Ulcer; Proportional Hazards Models; Prospective Studies; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides | 2000 |
Celecoxib versus diclofenac in the management of osteoarthritis of the knee.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Aspartate Aminotransferases; Celecoxib; Creatinine; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Female; Gastrointestinal Diseases; Hemoglobins; Humans; Knee Joint; Male; Middle Aged; Osteoarthritis, Knee; Pain Measurement; Pyrazoles; Severity of Illness Index; Sulfonamides; Treatment Outcome | 2001 |
Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular System; Celecoxib; Coronary Thrombosis; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Female; Humans; Ibuprofen; Male; Pyrazoles; Sulfonamides | 2002 |
Dyspepsia tolerability from the patients' perspective: a comparison of celecoxib with diclofenac.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Diclofenac; Double-Blind Method; Dyspepsia; Female; Humans; Male; Middle Aged; Osteoarthritis; Pyrazoles; Severity of Illness Index; Sulfonamides; Surveys and Questionnaires | 2002 |
Anti-hyperalgesic effects of nimesulide: studies in rats and humans.
Topics: Aged; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Diclofenac; Double-Blind Method; Female; Humans; Hyperalgesia; Lactones; Male; Middle Aged; Models, Animal; Pyrazoles; Rats; Rats, Sprague-Dawley; Sulfonamides; Sulfones | 2002 |
Effects of celecoxib and diclofenac on blood pressure, renal function, and vasoactive prostanoids in young and elderly subjects.
Topics: Adult; Aged; Aging; Biomarkers; Blood Pressure; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Eicosanoids; Female; Glomerular Filtration Rate; Humans; Inulin; Isoenzymes; Kidney; Kidney Function Tests; Male; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Proteinuria; Pyrazoles; Renin-Angiotensin System; Sulfonamides; Time Factors | 2002 |
Rapid potentiation of endothelium-dependent vasodilation by estradiol in postmenopausal women is mediated via cyclooxygenase 2.
Topics: Acetylcholine; Aspirin; Body Mass Index; Celecoxib; Cholesterol; Cholesterol, HDL; Cross-Over Studies; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Drug Synergism; Endothelium, Vascular; Estradiol; Female; Humans; Isoenzymes; Kinetics; Laser-Doppler Flowmetry; Membrane Proteins; Middle Aged; Placebos; Postmenopause; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Triglycerides; Vasodilation | 2002 |
Efficacy and safety of diclofenac-cholestyramine and celecoxib in osteoarthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Celecoxib; Cholestyramine Resin; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Osteoarthritis; Pain Measurement; Pyrazoles; Sulfonamides | 2002 |
Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter pylori; Humans; Isoenzymes; Membrane Proteins; Omeprazole; Peptic Ulcer Hemorrhage; Probability; Prospective Studies; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Risk Factors; Secondary Prevention; Stomach Ulcer; Sulfonamides | 2002 |
Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib.
Topics: Adult; Aged; Aging; Alleles; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Celecoxib; Cross-Over Studies; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Cytochrome P-450 CYP2C9; Diclofenac; Double-Blind Method; Female; Genotype; Half-Life; Humans; Isoenzymes; Male; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides | 2003 |
Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Black People; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Celecoxib; Cross-Over Studies; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Female; Gastrointestinal Tract; Glomerular Filtration Rate; Hispanic or Latino; Humans; Hypertension; Isoenzymes; Kidney; Male; Membrane Proteins; Middle Aged; Osteoarthritis; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides | 2004 |
Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Drug Administration Schedule; Female; Humans; Isoenzymes; Logistic Models; Male; Membrane Proteins; Middle Aged; Organic Chemicals; Osteoarthritis, Knee; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides | 2004 |
Analgesic efficacy of a single dose of lumiracoxib compared with rofecoxib, celecoxib and placebo in the treatment of post-operative dental pain.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Female; Humans; Lactones; Male; Molar, Third; Organic Chemicals; Pain, Postoperative; Pyrazoles; Sulfonamides; Sulfones; Tooth Extraction; Treatment Outcome | 2004 |
Gastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritis.
Topics: Aged; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Female; Humans; Ibuprofen; Incidence; Male; Middle Aged; Organic Chemicals; Osteoarthritis; Peptic Ulcer; Pyrazoles; Risk Factors; Sulfonamides | 2004 |
Lumiracoxib.
Topics: Administration, Oral; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Drug Administration Schedule; Drug Evaluation, Preclinical; Female; Half-Life; Humans; Male; Molecular Structure; New Zealand; Organic Chemicals; Osteoarthritis; Oxycodone; Pain; Pyrazoles; Sulfonamides; Terminology as Topic; World Health Organization | 2004 |
Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial.
Topics: Adult; Aged; Arthritis; Celecoxib; Diclofenac; Double-Blind Method; Drug Therapy, Combination; Dyspepsia; Female; Humans; Male; Middle Aged; Omeprazole; Peptic Ulcer; Prospective Studies; Pyrazoles; Recurrence; Sulfonamides | 2004 |
Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo.
Topics: Adult; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Female; Humans; Male; Membrane Proteins; Middle Aged; Organic Chemicals; Osteoarthritis, Knee; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Time Factors; Treatment Outcome | 2005 |
Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib.
Topics: Activities of Daily Living; Administration, Oral; Adult; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Organic Chemicals; Osteoarthritis, Knee; Placebos; Pyrazoles; Sulfonamides; Treatment Outcome | 2005 |
Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxib.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Organic Chemicals; Osteoarthritis, Knee; Pain; Pain Measurement; Prospective Studies; Pyrazoles; Sulfonamides; Treatment Outcome | 2006 |
Preoperative use of selective COX-II inhibitors for pain management in laparoscopic nissen fundoplication.
Topics: Adult; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Double-Blind Method; Female; Fundoplication; Humans; Lactones; Laparoscopy; Male; Pain, Postoperative; Preoperative Care; Prospective Studies; Pyrazoles; Sulfonamides; Sulfones | 2005 |
COX-2 inhibitors and pain after oral surgery - pertinent papers 2002-2003.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Ibuprofen; Injections, Intravenous; Isoxazoles; Lactones; Pain, Postoperative; Preanesthetic Medication; Prodrugs; Pyrazoles; Sulfonamides; Sulfones; Tooth Extraction | 2006 |
More pronounced inhibition of cyclooxygenase 2, increase in blood pressure, and reduction of heart rate by treatment with diclofenac compared with celecoxib and rofecoxib.
Topics: Blood Pressure; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Female; Heart Rate; Humans; Lactones; Male; Middle Aged; Pyrazoles; Sulfonamides; Sulfones | 2006 |
First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison with celecoxib [NCT00267215].
Topics: Aged; Analgesics; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Organic Chemicals; Osteoarthritis, Knee; Pain Measurement; Pyrazoles; Sulfonamides; Time Factors; Treatment Outcome | 2006 |
Long term NSAID treatment inhibits COX-2 synthesis in the knee synovial membrane of patients with osteoarthritis: differential proinflammatory cytokine profile between celecoxib and aceclofenac.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Blotting, Western; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Depression, Chemical; Diclofenac; Dinoprostone; Female; Gene Expression; Humans; Interleukin-1; Knee Joint; Male; Membrane Proteins; Osteoarthritis, Knee; Pyrazoles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfonamides; Synovial Membrane; Time Factors; Tumor Necrosis Factor-alpha | 2006 |
Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Naproxen; Osteoarthritis; Pain; Pyrazoles; Severity of Illness Index; Sulfonamides | 2006 |
A randomized database study in general practice yielded quality data but patient recruitment in routine consultation was not practical.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Databases, Factual; Diclofenac; Family Practice; Gastrointestinal Tract; Humans; Information Storage and Retrieval; Medical Records Systems, Computerized; Netherlands; Osteoarthritis; Patient Selection; Pyrazoles; Referral and Consultation; Software; Sulfonamides; Treatment Outcome | 2006 |
Efficacy and tolerability of celecoxib compared with diclofenac slow release in the treatment of acute ankle sprain in an Asian population.
Topics: Acute Disease; Adult; Ankle Injuries; Anti-Inflammatory Agents, Non-Steroidal; Asia; Blood Platelets; Celecoxib; Cyclooxygenase 2 Inhibitors; Delayed-Action Preparations; Diclofenac; Female; Humans; Male; Pain Measurement; Pyrazoles; Sprains and Strains; Sulfonamides; Treatment Outcome; Weight-Bearing | 2006 |
Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen.
Topics: Acid-Base Equilibrium; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Blood Pressure; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Edema; Female; Glomerular Filtration Rate; Heart; Humans; Hyponatremia; Ibuprofen; Kidney; Male; Middle Aged; Osteoarthritis; Pyrazoles; Sulfonamides | 2006 |
The associations between severity of early postoperative pain, chronic postsurgical pain and plasma concentration of stable nitric oxide products after breast surgery.
Topics: Acetaminophen; Adult; Aged; Analgesia; Anxiety; Breast Neoplasms; Bupivacaine; Celecoxib; Chronic Disease; Depression; Dextropropoxyphene; Diclofenac; Female; Humans; Isoxazoles; Mastectomy; Middle Aged; Morphine; Nerve Block; Nitric Oxide; Nociceptors; Pain Measurement; Pain, Postoperative; Pyrazoles; Sulfonamides | 2006 |
Stability of the patient acceptable symptomatic state over time in outcome criteria in ankylosing spondylitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Diclofenac; Female; Follow-Up Studies; Health Status Indicators; Humans; Male; Middle Aged; Pain Measurement; Patient Satisfaction; Prospective Studies; Pyrazoles; Remission Induction; Severity of Illness Index; Spondylitis, Ankylosing; Sulfonamides; Treatment Outcome | 2006 |
Evaluation of the patient acceptable symptom state in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis.
Topics: Aged; Celecoxib; Diclofenac; Double-Blind Method; Female; Humans; Male; Middle Aged; Osteoarthritis; Pain Measurement; Patient Satisfaction; Pyrazoles; Sulfonamides | 2007 |
Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Pain Measurement; Pyrazoles; Severity of Illness Index; Spondylitis, Ankylosing; Sulfonamides; Treatment Outcome | 2008 |
Lumiracoxib 400 mg compared with celecoxib 400 mg and placebo for treating pain following dental surgery: a randomized, controlled trial.
Topics: Adolescent; Adult; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Pain Measurement; Pain, Postoperative; Placebo Effect; Pyrazoles; Sulfonamides; Time Factors; Tooth Extraction; Tooth, Impacted; Treatment Outcome | 2008 |
Oral celecoxib versus oral diclofenac for post-perineal repair analgesia after spontaneous vaginal birth: a randomised trial.
Topics: Administration, Oral; Adult; Analgesia; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Delivery, Obstetric; Diclofenac; Episiotomy; Female; Humans; Pain Measurement; Perineum; Pregnancy; Pyrazoles; Rupture; Sulfonamides | 2008 |
Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis.
Topics: Aged; Arthralgia; Canada; Cardiovascular Diseases; Celecoxib; Chemical and Drug Induced Liver Injury; Cyclooxygenase 2 Inhibitors; Diclofenac; Double-Blind Method; Drug Administration Schedule; Europe; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Osteoarthritis; Pain Measurement; Pyrazoles; Sulfonamides; Time Factors; Treatment Outcome; United States | 2008 |
Analgesic effectiveness of celecoxib and diclofenac in patients with osteoarthritis of the hip requiring joint replacement surgery: a 12-week, multicenter, randomized, double-blind, parallel-group, double-dummy, noninferiority study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthroplasty, Replacement, Hip; Celecoxib; Diclofenac; Double-Blind Method; Female; Humans; Male; Middle Aged; Osteoarthritis, Hip; Pain Measurement; Pyrazoles; Sulfonamides; United Kingdom; Waiting Lists; Walking | 2008 |
Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 versus COX-1 in healthy subjects.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cross-Over Studies; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Diclofenac; Dinoprostone; Double-Blind Method; Etoricoxib; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridines; Sulfonamides; Sulfones; Thromboxane B2 | 2008 |
Long-term NSAID treatment directly decreases COX-2 and mPGES-1 production in the articular cartilage of patients with osteoarthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cartilage, Articular; Celecoxib; Chondrocytes; Cyclooxygenase 2; Diclofenac; Dinoprostone; Down-Regulation; Female; Humans; Interleukin-1; Male; Nitric Oxide; Osteoarthritis, Knee; Pyrazoles; Sulfonamides; Synovial Membrane | 2008 |
Clinical trial: the impact of cyclooxygenase inhibitors on gastrointestinal recovery after major surgery - a randomized double blind controlled trial of celecoxib or diclofenac vs. placebo.
Topics: Adult; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Female; Gastrointestinal Motility; Humans; Ileus; Length of Stay; Male; Middle Aged; Pain, Postoperative; Postoperative Complications; Pyrazoles; South Australia; Stomach Diseases; Sulfonamides; Treatment Outcome | 2009 |
Incidence of gastroduodenal ulcers during treatment with celecoxib or diclofenac: pooled results from three 12-week trials in Chinese patients with osteoarthritis or rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Celecoxib; China; Comorbidity; Cyclooxygenase 2 Inhibitors; Diclofenac; Double-Blind Method; Endoscopy, Gastrointestinal; Female; Humans; Male; Middle Aged; Osteoarthritis; Peptic Ulcer; Pyrazoles; Sulfonamides; Young Adult | 2010 |
Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Lower Gastrointestinal Tract; Male; Middle Aged; Omeprazole; Osteoarthritis; Peptic Ulcer; Pyrazoles; Research Design; Risk Assessment; Risk Factors; Sulfonamides; Treatment Outcome; Upper Gastrointestinal Tract | 2010 |
Haemoglobin decreases in NSAID users over time: an analysis of two large outcome trials.
Topics: Adult; Aged; Anemia; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Double-Blind Method; Drug Therapy, Combination; Female; Hemoglobins; Humans; Male; Middle Aged; Osteoarthritis; Prospective Studies; Pyrazoles; Sulfonamides | 2011 |
Risk factors associated with a decrease ≥2 g/dL in haemoglobin and/or ≥10% haematocrit in osteoarthritis patients taking celecoxib or a nonselective NSAID plus a PPI in a large randomised controlled trial (CONDOR).
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Double-Blind Method; Female; Hematocrit; Hemoglobins; Humans; Male; Middle Aged; Omeprazole; Osteoarthritis; Proton Pump Inhibitors; Pyrazoles; Risk Factors; Sulfonamides | 2012 |
Efficacy and safety of celecoxib versus diclofenac and omeprazole in elderly arthritis patients: a subgroup analysis of the CONDOR trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Double-Blind Method; Humans; Omeprazole; Prospective Studies; Pyrazoles; Sulfonamides | 2012 |
Celecoxib does not affect the release of hyaluronic acid in end stage osteoarthritic joints.
Topics: Aged; Aged, 80 and over; Cartilage, Articular; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Female; Humans; Hyaluronic Acid; Interleukin-1beta; Knee Joint; Male; Middle Aged; Osteoarthritis, Knee; Pyrazoles; Sulfonamides; Synovial Fluid; Tumor Necrosis Factor-alpha | 2013 |
A phase 2 study evaluating the efficacy and safety of a novel, proprietary, nano-formulated, lower dose oral diclofenac.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Diclofenac; Double-Blind Method; Female; Humans; Male; Middle Aged; Molar, Third; Nanotechnology; Pain, Postoperative; Pyrazoles; Sulfonamides; Tooth Extraction; Young Adult | 2012 |
The effects of nonsteroidal anti-inflammatory drugs on clinical outcomes, synovial fluid cytokine concentration and signal transduction pathways in knee osteoarthritis. A randomized open label trial.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Cytokines; Diclofenac; Female; Humans; Ibuprofen; Male; Middle Aged; Osteoarthritis, Knee; Pyrazoles; Quality of Life; Signal Transduction; Sulfonamides; Synovial Fluid; Treatment Outcome | 2013 |
Amelioration of small bowel injury by switching from nonselective nonsteroidal anti-inflammatory drugs to celecoxib in rheumatoid arthritis patients: a pilot study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Capsule Endoscopy; Celecoxib; Cytokines; Diclofenac; Drug Substitution; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Indomethacin; Intestinal Mucosa; Intestine, Small; Male; Middle Aged; Phenylpropionates; Pilot Projects; Prospective Studies; Pyrazoles; Severity of Illness Index; Single-Blind Method; Sulfonamides | 2014 |
Celecoxib Versus Diclofenac in Mild to Moderate Depression Management Among Breast Cancer Patients: A Double-Blind, Placebo-Controlled, Randomized Trial.
Topics: Analgesics; Antidepressive Agents; Breast Neoplasms; Celecoxib; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Depression; Diclofenac; Double-Blind Method; Female; Humans; Middle Aged; Quality of Life | 2015 |
Celecoxib versus diclofenac for the treatment of ankylosing spondylitis: 12-week randomized study in Norwegian patients.
Topics: Celecoxib; Diclofenac; Endpoint Determination; Humans; Norway; Spondylitis, Ankylosing; Treatment Outcome | 2016 |
Combined application of diclofenac and celecoxib with an opioid yields superior efficacy in metastatic bone cancer pain: a randomized controlled trial.
Topics: Adult; Aged; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Bone Neoplasms; Cancer Pain; Celecoxib; Diclofenac; Female; Humans; Male; Middle Aged; Morphine; Pain Measurement; Treatment Outcome | 2017 |
Efficacy and safety of adalimumab by intra-articular injection for moderate to severe knee osteoarthritis: An open-label randomized controlled trial.
Topics: Adalimumab; Aged; Antirheumatic Agents; Celecoxib; Diclofenac; Female; Humans; Hyaluronic Acid; Ibuprofen; Injections, Intra-Articular; Male; Meloxicam; Middle Aged; Osteoarthritis, Knee; Pain; Pain Measurement; Patient Safety; Pilot Projects; Severity of Illness Index; Thiazines; Thiazoles; Treatment Outcome | 2018 |
Clinical therapeutic effect and safety of celecoxib in treating knee osteoarthritis.
Topics: Administration, Oral; Aged; Aged, 80 and over; Blood Sedimentation; Celecoxib; Diclofenac; Drug Therapy, Combination; Female; Humans; Hyaluronic Acid; Injections, Intra-Articular; Male; Middle Aged; Osteoarthritis, Knee; Pain Measurement; Quality of Life; Treatment Outcome | 2018 |
Efficacy of celecoxib as preemptive analgesia for patients undergoing laparoscopic inguinal hernia repair: a randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Analgesia; Anesthesia, General; Celecoxib; Diclofenac; Female; Hernia, Inguinal; Herniorrhaphy; Humans; Laparoscopy; Levobupivacaine; Male; Middle Aged; Nerve Block; Pain, Postoperative; Time Factors; Treatment Outcome; Young Adult | 2021 |
Long-Term Safety and Efficacy of Subcutaneous Tanezumab Versus Nonsteroidal Antiinflammatory Drugs for Hip or Knee Osteoarthritis: A Randomized Trial.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Blocking; Antibodies, Monoclonal, Humanized; Celecoxib; Diclofenac; Disease Progression; Double-Blind Method; Female; Fractures, Bone; Fractures, Spontaneous; Humans; Injections, Subcutaneous; Intra-Articular Fractures; Male; Middle Aged; Naproxen; Nerve Growth Factor; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteonecrosis; Treatment Outcome | 2021 |
Randomized double-blind, placebo-controlled study of topical diclofenac in the prevention of hand-foot syndrome in patients receiving capecitabine (the D-TORCH study).
Topics: Antimetabolites, Antineoplastic; Capecitabine; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Hand-Foot Syndrome; Humans | 2022 |
Pharmacokinetic Interactions Between Tegoprazan and Naproxen, Aceclofenac, and Celecoxib in Healthy Korean Male Subjects.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Benzene Derivatives; Celecoxib; Cross-Over Studies; Diclofenac; Humans; Imidazoles; Male; Naproxen; Republic of Korea; Tablets | 2022 |
167 other study(ies) available for diclofenac and celecoxib
| Article | Year |
|---|---|
The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor.
Topics: Administration, Oral; Animals; Biological Availability; CHO Cells; Cricetinae; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Enzyme Inhibitors; Humans; Indomethacin; Inhibitory Concentration 50; Isoenzymes; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Rats; Sulfones | 1999 |
The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs.
Topics: Adenosine Triphosphate; Alprostadil; Animals; Anti-Inflammatory Agents, Non-Steroidal; Biological Transport; Cell Line; Cell Membrane; Diffusion; Dinoprost; Dinoprostone; Dose-Response Relationship, Drug; Humans; Insecta; Multidrug Resistance-Associated Proteins; Prostaglandins; Prostaglandins A; Prostaglandins F; Ribosomal Proteins; RNA Interference; RNA, Small Interfering; Thromboxane B2; Time Factors | 2003 |
Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition.
Topics: Animals; Binding Sites; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Celecoxib; Crystallography, X-Ray; Cyclooxygenase 2; Intraocular Pressure; Isoenzymes; Isoxazoles; Kinetics; Lactones; Models, Molecular; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rabbits; Structure-Activity Relationship; Sulfonamides; Sulfones | 2004 |
Extraction and visualization of potential pharmacophore points using support vector machines: application to ligand-based virtual screening for COX-2 inhibitors.
Topics: Binding Sites; Cell Line; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Enzyme-Linked Immunosorbent Assay; Humans; Ligands; Models, Molecular; Quantitative Structure-Activity Relationship; Thrombin | 2005 |
Selective cyclooxygenase-2 inhibitors from Calophyllum membranaceum.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Calophyllum; Cyclooxygenase 2 Inhibitors; Drugs, Chinese Herbal; Inhibitory Concentration 50; Molecular Structure; Plants, Medicinal; Xanthones | 2005 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Diaryl-dithiolanes and -isothiazoles: COX-1/COX-2 and 5-LOX-inhibitory, *OH scavenging and anti-adhesive activities.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Adhesion; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Free Radical Scavengers; Hydroxyl Radical; Lipoxygenase Inhibitors; Macrophage-1 Antigen; Mice; Neutrophils; Peritonitis; Sulfhydryl Compounds; Thiazoles | 2009 |
Fenbufen based 3-[5-(substituted aryl)-1,3,4-oxadiazol-2-yl]-1-(biphenyl-4-yl)propan-1-ones as safer antiinflammatory and analgesic agents.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Cyclooxygenase Inhibitors; Female; Lipid Peroxidation; Male; Mice; Oxadiazoles; Pain Measurement; Phenylbutyrates; Prostaglandin-Endoperoxide Synthases; Rats; Stomach; Ulcer | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Synthesis, anti-inflammatory activity and COX-1/COX-2 inhibition of novel substituted cyclic imides. Part 1: Molecular docking study.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Crystallography, X-Ray; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Disease Models, Animal; Edema; Hydrogen Bonding; Imides; Male; Models, Molecular; Molecular Structure; Rats; Rats, Sprague-Dawley; Sheep; Stereoisomerism; Structure-Activity Relationship | 2011 |
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
Topics: Glutathione; Pharmacology; Sulfur Radioisotopes | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Rationally designed hybrid molecules with appreciable COX-2 inhibitory and anti-nociceptive activities.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Drug Design; Female; Male; Mice; Models, Molecular; Molecular Structure; Structure-Activity Relationship | 2014 |
Rational design, synthesis and evaluation of chromone-indole and chromone-pyrazole based conjugates: identification of a lead for anti-inflammatory drug.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Capsaicin; Chromones; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Indoles; Mice; Models, Molecular; Molecular Structure; Pain; Pain Measurement; Pyrazoles; Structure-Activity Relationship | 2014 |
Synthesis, pharmacological screening and in silico studies of new class of Diclofenac analogues as a promising anti-inflammatory agents.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Computer Simulation; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Edema; Mice; Models, Molecular; Molecular Structure; Rats; Structure-Activity Relationship | 2014 |
Design and synthesis of novel 2-phenyl-5-(1,3-diphenyl-1H-pyrazol-4-yl)-1,3,4-oxadiazoles as selective COX-2 inhibitors with potent anti-inflammatory activity.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Chemistry Techniques, Synthetic; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Humans; Male; Mice; Molecular Docking Simulation; Oxadiazoles; Protein Conformation; Rats; Stomach Ulcer; Structure-Activity Relationship; Substrate Specificity | 2014 |
2-(2-Arylphenyl)benzoxazole As a Novel Anti-Inflammatory Scaffold: Synthesis and Biological Evaluation.
Topics: | 2014 |
Propyphenazone-based analogues as prodrugs and selective cyclooxygenase-2 inhibitors.
Topics: | 2014 |
Structure-based design of phthalimide derivatives as potential cyclooxygenase-2 (COX-2) inhibitors: anti-inflammatory and analgesic activities.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Cyclooxygenase 2 Inhibitors; Drug Design; Edema; Male; Models, Molecular; Molecular Structure; Phthalimides; Rats; Rats, Sprague-Dawley | 2015 |
Indole based peptidomimetics as anti-inflammatory and anti-hyperalgesic agents: Dual inhibition of 5-LOX and COX-2 enzymes.
Topics: Animals; Anti-Inflammatory Agents; Catalytic Domain; Crystallography, X-Ray; Cyclooxygenase 2 Inhibitors; Hyperalgesia; Indoles; Inhibitory Concentration 50; Lipoxygenase Inhibitors; Mice; Molecular Docking Simulation; Molecular Structure; Peptidomimetics | 2015 |
Synthesis, anti-inflammatory, ulcerogenic and cyclooxygenase activities of indenopyrimidine derivatives.
Topics: Animals; Anti-Inflammatory Agents; Anti-Ulcer Agents; Binding Sites; Carrageenan; Catalytic Domain; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Edema; Half-Life; Molecular Docking Simulation; Pyrazoles; Pyrimidines; Rats; Stomach Ulcer; Structure-Activity Relationship | 2016 |
Rational Design of Small Peptides for Optimal Inhibition of Cyclooxygenase-2: Development of a Highly Effective Anti-Inflammatory Agent.
Topics: Animals; Anti-Inflammatory Agents; Calorimetry; Carbon-13 Magnetic Resonance Spectroscopy; Cyclooxygenase 2 Inhibitors; Drug Design; Female; Humans; Male; Mice; Peptides; Proton Magnetic Resonance Spectroscopy; Quantitative Structure-Activity Relationship; Spectrometry, Mass, Electrospray Ionization | 2016 |
Synthesis, anti-inflammatory, analgesic, COX-1/2 inhibitory activities and molecular docking studies of substituted 2-mercapto-4(3H)-quinazolinones.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Chemistry Techniques, Synthetic; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Mice; Molecular Docking Simulation; Protein Conformation; Quinazolinones | 2016 |
Design, synthesis of 2,3-disubstitued 4(3H)-quinazolinone derivatives as anti-inflammatory and analgesic agents: COX-1/2 inhibitory activities and molecular docking studies.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Cyclooxygenase Inhibitors; Drug Design; Inhibitory Concentration 50; Mice; Molecular Docking Simulation; Quinazolinones; Spectrum Analysis | 2016 |
Synthesis of phenylpiperazine derivatives of 1,4-benzodioxan as selective COX-2 inhibitors and anti-inflammatory agents.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Catalytic Domain; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dioxanes; Dose-Response Relationship, Drug; Edema; Humans; Male; Mice; Molecular Docking Simulation; Molecular Structure; Piperazines; Rats; Structure-Activity Relationship | 2016 |
Synthesis, anti-inflammatory, cyclooxygenases inhibitions assays and histopathological study of poly-substituted 1,3,5-triazines: Confirmation of regiospecific pyrazole cyclization by HMBC.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Chemistry Techniques, Synthetic; Cyclization; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Design; Male; Molecular Docking Simulation; Protein Conformation; Pyrazoles; Rats; Stereoisomerism; Structure-Activity Relationship; Triazines; Ulcer | 2017 |
New arylpyrazoline-coumarins: Synthesis and anti-inflammatory activity.
Topics: Animals; Ankle Joint; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Cell Survival; Cells, Cultured; Coumarins; Crystallography, X-Ray; Dose-Response Relationship, Drug; Edema; Interleukin-6; Lipopolysaccharides; Male; Mice; Models, Molecular; Molecular Structure; Nitric Oxide; Pyrazoles; Rats; Rats, Sprague-Dawley; RAW 264.7 Cells; Structure-Activity Relationship; Tumor Necrosis Factor-alpha | 2017 |
Design, synthesis, and biological evaluation of some novel indolizine derivatives as dual cyclooxygenase and lipoxygenase inhibitor for anti-inflammatory activity.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Carrageenan; Cyclooxygenase Inhibitors; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Edema; Female; Indolizines; Lipoxygenase; Lipoxygenase Inhibitors; Male; Mice; Molecular Structure; Prostaglandin-Endoperoxide Synthases; Rats; Structure-Activity Relationship; Ulcer | 2017 |
Novel click modifiable thioquinazolinones as anti-inflammatory agents: Design, synthesis, biological evaluation and docking study.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonate 15-Lipoxygenase; Cell Differentiation; Click Chemistry; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Female; Humans; Lipoxygenase Inhibitors; Macrophages; Molecular Docking Simulation; Molecular Structure; Quinazolinones; Rats; Rats, Wistar; Structure-Activity Relationship; Sulfhydryl Compounds; Tumor Cells, Cultured | 2018 |
Tackling neuroinflammation and cholinergic deficit in Alzheimer's disease: Multi-target inhibitors of cholinesterases, cyclooxygenase-2 and 15-lipoxygenase.
Topics: Acetylcholine; Alzheimer Disease; Animals; Cell Line; Cholinesterase Inhibitors; Cyclooxygenase 2 Inhibitors; Drug Design; Humans; Inflammation; Lipoxygenase Inhibitors; Mice; Molecular Docking Simulation; Neurons; PC12 Cells; Rats; Semicarbazides; Triazoles | 2019 |
Shooting three inflammatory targets with a single bullet: Novel multi-targeting anti-inflammatory glitazones.
Topics: Animals; Anti-Inflammatory Agents; Arachidonate 15-Lipoxygenase; Cyclooxygenase 2 Inhibitors; Drug Design; Humans; Ligands; Molecular Docking Simulation; PPAR gamma; Protein Binding; Thiazolidinediones | 2019 |
Design of balanced COX inhibitors based on anti-inflammatory and/or COX-2 inhibitory ascidian metabolites.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Survival; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Drug Design; Humans; Mice; Models, Molecular; Molecular Structure; RAW 264.7 Cells; Sheep; Structure-Activity Relationship; Urochordata | 2019 |
Design, synthesis, in-vitro, in-vivo and in-silico studies of pyrrolidine-2,5-dione derivatives as multitarget anti-inflammatory agents.
Topics: Albumins; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonate 5-Lipoxygenase; Carrageenan; Cyclooxygenase 2; Dose-Response Relationship, Drug; Drug Design; Edema; Enzyme Inhibitors; Female; Humans; Male; Mice; Mice, Inbred BALB C; Molecular Docking Simulation; Molecular Structure; Pyrrolidines; Structure-Activity Relationship | 2020 |
Modification of the lead molecule: Tryptophan and piperidine appended triazines reversing inflammation and hyeperalgesia in rats.
Topics: Acetic Acid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Formaldehyde; Humans; Hyperalgesia; Inflammation; Molecular Docking Simulation; Molecular Structure; Piperidines; Rats; Rats, Wistar; Structure-Activity Relationship; Triazines; Tryptophan | 2020 |
Investigations on substituted (2-aminothiazol-5-yl)(imidazo[1,2-a]pyridin-3-yl)methanones for the treatment of Alzheimer's disease.
Topics: Aluminum Chloride; Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Drug; Edema; Female; Formaldehyde; Imidazoles; Inflammation; Male; Molecular Structure; Neuroprotective Agents; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship | 2021 |
Design, Synthesis, and Activity Evaluation of Stereoconfigured Tartarate Derivatives as Potential Anti-inflammatory Agents
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Drug Design; Edema; Female; Humans; Lipoxygenase; Lipoxygenase Inhibitors; Male; Mice; Molecular Structure; Stereoisomerism; Structure-Activity Relationship; Tartrates | 2021 |
Interactions between inducible isoforms of nitric oxide synthase and cyclo-oxygenase in vivo: investigations using the selective inhibitors, 1400W and celecoxib.
Topics: 6-Ketoprostaglandin F1 alpha; Amidines; Analysis of Variance; Aniline Compounds; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzylamines; Celecoxib; Crotonates; Cyclooxygenase 2; Dexamethasone; Diclofenac; Enzyme Inhibitors; Hydroxybutyrates; Isoenzymes; Male; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitriles; Nitrites; Nitrogen Dioxide; omega-N-Methylarginine; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Wistar; Sulfonamides; Toluidines | 1998 |
Substrate-dependent effect of acetonitrile on human liver microsomal cytochrome P450 2C9 (CYP2C9) activity.
Topics: Acetonitriles; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Blocking; Anticonvulsants; Aryl Hydrocarbon Hydroxylases; Celecoxib; Cytochrome P-450 CYP2C9; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Diclofenac; Enzyme Inhibitors; Humans; Hypoglycemic Agents; In Vitro Techniques; Microsomes, Liver; Phenotype; Phenytoin; Pyrazoles; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases; Sulfonamides; Tolbutamide | 2000 |
Nonsteroidal anti-inflammatory drugs for perioperative pain control.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Butanones; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Etodolac; Humans; Ibuprofen; Indomethacin; Ketorolac; Lactones; Nabumetone; Naproxen; Pain, Postoperative; Piroxicam; Pyrazoles; Sulfonamides; Sulfones; Time Factors | 2001 |
[Renal tolerance of selective inhibitors of cyclooxygenase type 2].
Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Diclofenac; Humans; Kidney; Kidney Diseases; Lactones; Naproxen; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Pyrazoles; Rats; Risk Factors; Sulfonamides; Sulfones; Water-Electrolyte Imbalance | 2001 |
Participation of COX, IL-1 beta and TNF alpha in formalin-induced inflammatory pain.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Blocking; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Female; Formaldehyde; Inflammation; Interleukin-1; Male; Pain; Pain Measurement; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Wistar; Sulfonamides; Tumor Necrosis Factor-alpha | 2001 |
Comparison of the antinociceptive effect of celecoxib, diclofenac and resveratrol in the formalin test.
Topics: Analgesia; Animals; Anti-Inflammatory Agents, Non-Steroidal; Behavior, Animal; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Female; Formaldehyde; Inflammation; Pain; Pyrazoles; Rats; Rats, Wistar; Resveratrol; Stilbenes; Sulfonamides | 2002 |
Digging for data from the COX-2 trials.
Topics: Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Humans; Ibuprofen; Peptic Ulcer; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Treatment Outcome | 2002 |
Are selective COX 2 inhibitors superior to traditional NSAIDs? Pharmacia's response to editorial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Diclofenac; Drug Therapy, Combination; Humans; Ibuprofen; Peptic Ulcer; Pyrazoles; Sulfonamides | 2002 |
Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cohort Studies; Cyclooxygenase 2; Diclofenac; Drug Combinations; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Hospitalization; Humans; Isoenzymes; Lactones; Male; Membrane Proteins; Misoprostol; Multivariate Analysis; Proportional Hazards Models; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Risk Factors; Sulfonamides; Sulfones | 2002 |
[Analgesic in osteoporosis. Why so conservative with dosage?].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Humans; Ibuprofen; Lactones; Middle Aged; Osteoporosis; Pyrazoles; Risk Factors; Sulfonamides; Sulfones | 2002 |
NSAIDs, Helicobacter pylori, and Pandora's Box.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Isoenzymes; Membrane Proteins; Omeprazole; Peptic Ulcer; Peptic Ulcer Hemorrhage; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides | 2002 |
Non-steroidal anti-inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Corpus Striatum; Diclofenac; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Gentisates; Hydroxybenzoates; Hydroxyl Radical; In Vitro Techniques; Male; Mortality; Neurodegenerative Diseases; Neuroprotective Agents; Pyrazoles; Rats; Rats, Inbred Strains; Rats, Sprague-Dawley; Sodium Salicylate; Sulfonamides | 2003 |
Celecoxib versus diclofenac and omeprazole to prevent recurrent ulcer bleeding.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Humans; Isoenzymes; Membrane Proteins; Omeprazole; Peptic Ulcer Hemorrhage; Prostaglandin-Endoperoxide Synthases; Proton Pump Inhibitors; Pyrazoles; Risk Factors; Secondary Prevention; Sulfonamides | 2003 |
Celecoxib versus diclofenac and omeprazole to prevent recurrent ulcer bleeding.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Celecoxib; Contraindications; Cyclooxygenase Inhibitors; Diclofenac; Drug Therapy, Combination; Humans; Kidney Diseases; Omeprazole; Peptic Ulcer Hemorrhage; Pyrazoles; Risk Factors; Secondary Prevention; Sulfonamides | 2003 |
Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension.
Topics: Acetylcholine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Dinoprost; Endothelium, Vascular; Enzyme Inhibitors; F2-Isoprostanes; Hypertension; Interleukin-1; Isoenzymes; Lactones; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Oxidative Stress; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Inbred Dahl; Safety; Sodium Chloride, Dietary; Sulfonamides; Sulfones; Vasodilation | 2003 |
Persistence with COX-2 inhibitors in managed care: an analysis of claims data.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Drug Utilization Review; Female; Health Care Costs; Humans; Ibuprofen; Insurance Claim Review; Isoenzymes; Lactones; Male; Managed Care Programs; Membrane Proteins; Middle Aged; Naproxen; Patient Compliance; Proportional Hazards Models; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Regression Analysis; Sulfonamides; Sulfones; United States | 2003 |
Celecoxib has a positive effect on the overall metabolism of hyaluronan and proteoglycans in human osteoarthritic cartilage.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cartilage, Articular; Celecoxib; Diclofenac; Dose-Response Relationship, Drug; Female; Humans; Hyaluronic Acid; In Vitro Techniques; Male; Middle Aged; Osteoarthritis; Proteoglycans; Pyrazoles; Sulfonamides | 2003 |
Endoplasmic reticulum stress response is involved in nonsteroidal anti-inflammatory drug-induced apoptosis.
Topics: Activating Transcription Factor 4; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Blotting, Northern; Celecoxib; Cell Line; Cell Survival; Cells, Cultured; Diclofenac; DNA-Binding Proteins; Dose-Response Relationship, Drug; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Enzyme Activation; Gastric Mucosa; Genes, Reporter; Guinea Pigs; Heat-Shock Proteins; Hydrogen Peroxide; Ibuprofen; Immunoblotting; Indomethacin; Luciferases; Macrophages; Microscopy, Fluorescence; Molecular Chaperones; Plasmids; Pyrazoles; Regulatory Factor X Transcription Factors; RNA, Messenger; Sulfonamides; Time Factors; Transcription Factors; Transcription, Genetic; Transfection; X-Box Binding Protein 1 | 2004 |
[Influence of non-selective and cyclooxygenase-II-selective cyclooxygenase-inhibitors on primary human osteoblasts].
Topics: Alkaline Phosphatase; Anti-Inflammatory Agents, Non-Steroidal; Bony Callus; Celecoxib; Cell Differentiation; Cell Division; Cyclooxygenase Inhibitors; Diclofenac; Humans; Osteoblasts; Osteocalcin; Pyrazoles; Sulfonamides | 2004 |
COX-2-specific inhibitor or proton pump inhibitor plus traditional NSAID: is either approach sufficient for patients at highest risk of NSAID-induced ulcers?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Drug Therapy, Combination; Humans; Isoenzymes; Membrane Proteins; Omeprazole; Peptic Ulcer; Prostaglandin-Endoperoxide Synthases; Proton Pump Inhibitors; Pyrazoles; Sulfonamides | 2004 |
Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Flurbiprofen; Ibuprofen; Isoenzymes; Lactones; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Sprague-Dawley; Sulfonamides; Sulfones; Thrombosis | 2004 |
Cyclooxygenase-2 is expressed in neuroblastoma, and nonsteroidal anti-inflammatory drugs induce apoptosis and inhibit tumor growth in vivo.
Topics: Adrenal Gland Neoplasms; Adrenal Medulla; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Celecoxib; Cell Line, Tumor; Child; Child, Preschool; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Female; Humans; Infant; Infant, Newborn; Isoenzymes; Male; Membrane Proteins; Neuroblastoma; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Nude; Sulfonamides; Xenograft Model Antitumor Assays | 2004 |
Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs.
Topics: Animals; Antioxidants; Celecoxib; Cholesterol, LDL; Chromans; Cyclooxygenase Inhibitors; Diclofenac; Humans; Ibuprofen; Isoprostanes; Isoxazoles; Lactones; Meloxicam; Naproxen; Oxidation-Reduction; Pyrazoles; Sulfonamides; Sulfones; Thiazines; Thiazoles | 2004 |
The effects of selective and nonselective cyclooxygenase inhibitors on endothelin-1-induced fever in rats.
Topics: Animals; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Dinoprost; Dinoprostone; Dose-Response Relationship, Drug; Endothelin-1; Fever; Indomethacin; Injections, Intraperitoneal; Injections, Intraventricular; Intubation, Gastrointestinal; Lipopolysaccharides; Male; Organic Chemicals; Pyrazoles; Rats; Rats, Wistar; Sulfonamides | 2005 |
Selective COX-2 inhibitors and renal injury in salt-sensitive hypertension.
Topics: Animals; Blood Pressure; Blood Vessels; C-Reactive Protein; CD8-Positive T-Lymphocytes; Celecoxib; Cell Count; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Hemodynamics; Hypertension; Immunohistochemistry; Kidney; Kidney Cortex; Kidney Glomerulus; Lactones; Monocytes; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Inbred Dahl; RNA, Messenger; Sodium Chloride; Sulfonamides; Sulfones | 2005 |
[Role of prostaglandin E2 in regulation of urine excretion in saluresis, water and osmotic diuresis in rat].
Topics: Animals; Celecoxib; Chlorides; Cyclooxygenase Inhibitors; Diclofenac; Dinoprostone; Diuresis; Diuretics; Furosemide; Male; Natriuresis; Osmosis; Pyrazoles; Rats; Rats, Wistar; Sulfonamides; Urination; Water | 2004 |
Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bias; Case-Control Studies; Celecoxib; Confounding Factors, Epidemiologic; Cyclooxygenase Inhibitors; Diclofenac; Female; Humans; Ibuprofen; Lactones; Male; Middle Aged; Myocardial Infarction; Naproxen; Odds Ratio; Pyrazoles; Risk Factors; Sulfonamides; Sulfones | 2005 |
SKI306X, an oriental herbal mixture, suppresses gastric leukotriene B4 synthesis without causing mucosal injury and the diclofenac-induced gastric lesions.
Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Depression, Chemical; Diclofenac; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Eicosanoids; Gastric Mucosa; Leukotriene B4; Male; Peroxidase; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Sprague-Dawley; Stomach Ulcer; Sulfonamides | 2005 |
Influence of plasma protein on the potencies of inhibitors of cyclooxygenase-1 and -2.
Topics: Aspirin; Blood Platelets; Blood Proteins; Calcimycin; Calcium; Celecoxib; Cell Line; Cerebrospinal Fluid Proteins; Cyclooxygenase 1; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Dinoprostone; Humans; Indomethacin; Ionophores; Lactones; Meloxicam; Naproxen; Organ Specificity; Organic Chemicals; Protein Binding; Pyrazoles; Sodium Salicylate; Sulfonamides; Sulfones; Synovial Fluid; Thiazines; Thiazoles; Thromboxane A2 | 2006 |
Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis--a population-based survey.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cohort Studies; Cross-Sectional Studies; Diclofenac; Female; Humans; Indomethacin; Male; Middle Aged; Naproxen; Pain; Pain Measurement; Patient Satisfaction; Pyrazoles; Retreatment; Spondylitis, Ankylosing; Sulfonamides; Surveys and Questionnaires; Treatment Outcome | 2006 |
Effect of glutamate receptor antagonists and antirheumatic drugs on proliferation of synoviocytes in vitro.
Topics: Animals; Antirheumatic Agents; Benzodiazepines; Benzodiazepinones; Celecoxib; Cell Line; Cell Proliferation; Cell Survival; Diclofenac; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Inhibitory Concentration 50; Methotrexate; Naproxen; Pyrazoles; Quinoxalines; Sulfasalazine; Sulfonamides; Synovial Membrane | 2006 |
Tolerance of diclofenac after hypersensitivity to celecoxib and to nabumetone.
Topics: Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Drug Hypersensitivity; Female; Humans; Knee Joint; Nabumetone; Osteoarthritis; Pyrazoles; Sulfonamides; Treatment Outcome | 2006 |
Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Confidence Intervals; Cross-Over Studies; Cyclooxygenase 2 Inhibitors; Denmark; Diclofenac; Dose-Response Relationship, Drug; Female; Humans; Ibuprofen; Lactones; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Patient Readmission; Proportional Hazards Models; Pyrazoles; Recurrence; Registries; Retrospective Studies; Risk Factors; Sulfonamides; Sulfones | 2006 |
Inhibition of cyclooxygenase (COX)-2 affects endothelial progenitor cell proliferation.
Topics: Animals; Apoptosis; Aspirin; Caspase 3; Caspase 8; Caspases; Celecoxib; Cell Proliferation; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Endothelial Cells; Gene Expression Regulation, Enzymologic; Male; Membrane Proteins; Oncogene Protein v-akt; Phosphorylation; Pyrazoles; Rats; Rats, Sprague-Dawley; RNA, Messenger; Stem Cells; Sulfonamides | 2006 |
Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Computer Simulation; Coronary Disease; Cyclooxygenase Inhibitors; Diclofenac; Female; Heart Failure; Humans; Ibuprofen; Male; Middle Aged; Models, Statistical; Naproxen; Peptic Ulcer; Population Surveillance; Pyrazoles; Risk Assessment; Risk Factors; Stroke; Sulfonamides; United States | 2007 |
[A case of complete regression of hepatocellular carcinoma during administration of COX-2 inhibitor].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Female; Humans; Lactones; Liver Neoplasms; Pyrazoles; Sulfonamides; Sulfones | 2006 |
Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Female; Gastrointestinal Diseases; Humans; Ibuprofen; Lactones; Male; Multivariate Analysis; Myocardial Infarction; Naproxen; Pyrazoles; Rheumatic Diseases; Risk Assessment; Risk Factors; Sulfonamides; Sulfones | 2006 |
Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Prescriptions; Drug Utilization; Female; Hospitalization; Humans; Ibuprofen; Lactones; Male; Myocardial Infarction; Product Surveillance, Postmarketing; Proportional Hazards Models; Pyrazoles; Quebec; Retrospective Studies; Sex Factors; Sulfonamides; Sulfones | 2007 |
Mucosal acid causes gastric mucosal microcirculatory disturbance in nonsteroidal anti-inflammatory drug-treated rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Diclofenac; Dinoprostone; Endothelin-1; Gastric Acid; Gastric Mucosa; Male; Microcirculation; Pyrazoles; Rats; Rats, Sprague-Dawley; Regional Blood Flow; Sulfonamides | 2007 |
Effect of different cyclooxygenase inhibitors on gastric adaptive cytoprotection induced by 20% ethanol.
Topics: Animals; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Cytoprotection; Diclofenac; Dinoprostone; Dose-Response Relationship, Drug; Enzyme Inhibitors; Ethanol; Gastric Acid; Gastric Mucosa; Ibuprofen; Irritants; Male; Meloxicam; Membrane Proteins; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Pyrazoles; Rats; Rats, Wistar; Stomach Ulcer; Sulfonamides; Thiazines; Thiazoles | 2007 |
In vivo effects of amtolmetin guacyl on lipid peroxidation and antioxidant defence systems. Comparison with non-selective and COX-2 selective NSAIDs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Catalase; Celecoxib; Colon; Cyclooxygenase 2 Inhibitors; Diclofenac; Gastric Mucosa; Glucosephosphate Dehydrogenase; Glutathione; Glutathione Peroxidase; Glutathione Reductase; Glycine; Lipid Peroxidation; Liver; Male; Oxyphenonium; Pyrazoles; Pyrroles; Rats; Rats, Wistar; Sulfhydryl Compounds; Sulfonamides; Thiobarbituric Acid Reactive Substances; Tolmetin | 2007 |
An economic model of long-term use of celecoxib in patients with osteoarthritis.
Topics: Age Factors; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cost-Benefit Analysis; Diclofenac; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Long-Term Care; Male; Maximum Tolerated Dose; Middle Aged; Models, Economic; Naproxen; Osteoarthritis; Probability; Pyrazoles; Quality-Adjusted Life Years; Risk Factors; Sensitivity and Specificity; Severity of Illness Index; Sulfonamides | 2007 |
Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Case-Control Studies; Celecoxib; Cytochrome P-450 CYP2C9; Diclofenac; Female; Gene Frequency; Genetic Predisposition to Disease; Humans; Ibuprofen; Male; Middle Aged; Naproxen; Odds Ratio; Peptic Ulcer; Peptic Ulcer Hemorrhage; Piroxicam; Polymorphism, Single Nucleotide; Pyrazoles; Risk Assessment; Risk Factors; Sulfonamides | 2007 |
[Effective also in Bechterew disease].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Clinical Trials as Topic; Combined Modality Therapy; Diclofenac; Humans; Physical Therapy Modalities; Pyrazoles; Spondylitis, Ankylosing; Sulfonamides | 2007 |
Pro-inflammatory effect in mice of CvL, a lectin from the marine sponge Cliona varians.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chemotaxis, Leukocyte; Dexamethasone; Diclofenac; Disease Models, Animal; Edema; Inflammation; Lectins; Macrophages, Peritoneal; Mice; Mice, Inbred Strains; Peritonitis; Porifera; Pyrazoles; Sulfonamides | 2008 |
Response to Ray and colleagues: the called-for large clinical trial is already ongoing.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Celecoxib; Diclofenac; Humans; Omeprazole; Peptic Ulcer; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides | 2008 |
Intracellular effects of NSAIDs/ASA in oxidatively stressed human lens epithelial cells in culture.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cell Size; Cells, Cultured; Diclofenac; Epithelial Cells; Free Radical Scavengers; Glutathione; Humans; Hydrogen Peroxide; Indomethacin; Intracellular Membranes; Lens, Crystalline; Membrane Potential, Mitochondrial; Mitochondria; Oxidants; Oxidative Stress; Peroxides; Pyrazoles; Reactive Oxygen Species; Sulfonamides; Superoxides | 2008 |
Effects of selective and non-selective COX inhibitors on antigen-induced release of prostanoid mediators and bronchoconstriction in the isolated perfused and ventilated guinea pig lung.
Topics: Animals; Bronchoconstriction; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Diclofenac; Flurbiprofen; Guinea Pigs; Humans; Leukotrienes; Lung; Male; Ovalbumin; Piperazines; Prostaglandins; Pyrazoles; Sulfonamides; Thiazoles; Thromboxane A2; Thromboxane B2 | 2008 |
Comparison of antinociceptive efficacy and gastroprotection between celecoxib and diclofenac plus misoprostol in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Combinations; Female; Formaldehyde; Gastric Mucosa; Misoprostol; Pain Measurement; Pyrazoles; Rats; Rats, Wistar; Stomach Ulcer; Sulfonamides | 2007 |
[Articular cartilage in osteoarthritic patients: effects of diclofenac, celecoxib and glucosamine sulfate on inflammatory markers].
Topics: Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Cartilage, Articular; Celecoxib; Chondrocytes; Cyclooxygenase Inhibitors; Diclofenac; Enzyme-Linked Immunosorbent Assay; Glucosamine; Humans; Matrix Metalloproteinases; Nitric Oxide; Osteoarthritis; Pyrazoles; Sulfonamides | 2007 |
Anti-inflammatory drugs suppress proliferation and induce apoptosis through altering expressions of cell cycle regulators and pro-apoptotic factors in cultured human osteoblasts.
Topics: Annexin A5; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Celecoxib; Cell Cycle; Cell Proliferation; Cells, Cultured; Cyclooxygenase 2 Inhibitors; Dexamethasone; Diclofenac; Dose-Response Relationship, Drug; Humans; Immunohistochemistry; Indomethacin; Ketorolac; L-Lactate Dehydrogenase; Osteoblasts; Piroxicam; Propidium; Pyrazoles; RNA, Messenger; Sulfonamides; Thymidine | 2009 |
Comparison of mechanical allodynia and the affective component of inflammatory pain in rats.
Topics: Analgesics, Non-Narcotic; Animals; Behavior, Animal; Celecoxib; Central Nervous System Agents; Diclofenac; Disease Models, Animal; Dose-Response Relationship, Drug; Duloxetine Hydrochloride; Escape Reaction; Fluoxetine; Inflammation; Male; Motor Activity; Neuropsychological Tests; Pain; Pain Measurement; Physical Stimulation; Pyrazoles; Rats; Rats, Sprague-Dawley; Scopolamine; Sulfonamides; Thiophenes; Treatment Outcome | 2010 |
Synthesis, ex vivo and in vitro hydrolysis study of an indoline derivative designed as an anti-inflammatory with reduced gastric ulceration properties.
Topics: Animals; Anti-Inflammatory Agents; Carrageenan; Celecoxib; Diclofenac; Drug Design; Hydrolysis; Indoles; Lactams; Male; Models, Molecular; Pyrazoles; Rats; Rats, Wistar; Stomach Ulcer; Sulfonamides | 2009 |
The effects of celecoxib, a COX-2 selective inhibitor, on acute inflammation induced in irradiated rats.
Topics: Acute Disease; Animals; Anti-Inflammatory Agents; Celecoxib; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Gamma Rays; Inflammation; Male; Pyrazoles; Radiation Injuries, Experimental; Rats; Rats, Wistar; Sulfonamides | 2009 |
Differential effects of non-steroidal anti-inflammatory drugs on mitochondrial dysfunction during oxidative stress.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzeneacetamides; Benzophenones; Bromobenzenes; Celecoxib; Diclofenac; Ketorolac Tromethamine; Male; Membrane Potentials; Mitochondria, Liver; Molecular Structure; Oxidative Stress; Permeability; Phenylacetates; Pyrazoles; Rats; Rats, Sprague-Dawley; Sulfonamides; Temperature; Time Factors | 2009 |
Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cohort Studies; Coronary Artery Disease; Cyclooxygenase 2 Inhibitors; Diclofenac; Female; Follow-Up Studies; Hospitalization; Humans; Ibuprofen; Incidence; Lactones; Male; Middle Aged; Myocardial Infarction; Naproxen; Outpatients; Pyrazoles; Retrospective Studies; Risk Factors; Stroke; Sulfonamides; Sulfones; Tennessee | 2009 |
Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDS in the treatment of ankylosing spondylitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bayes Theorem; Celecoxib; Cost-Benefit Analysis; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Costs; Drug-Related Side Effects and Adverse Reactions; Etoricoxib; Humans; Markov Chains; Meta-Analysis as Topic; Models, Economic; Naproxen; Pyrazoles; Pyridines; Quality-Adjusted Life Years; Severity of Illness Index; Spondylitis, Ankylosing; Sulfonamides; Sulfones; Treatment Outcome; United Kingdom | 2010 |
The role of NF-κB and PPARγ in experimentally induced colorectal cancer and chemoprevention by cyclooxygenase-2 inhibitors.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blotting, Western; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Diclofenac; Immunohistochemistry; Male; NF-kappa B; PPAR gamma; Pyrazoles; Rats; Rats, Sprague-Dawley; Sulfonamides | 2010 |
[Risk of anastomotic leakage in postoperative treatment with non-steroidal anti-inflammatory drugs].
Topics: Anastomosis, Surgical; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Humans; Postoperative Complications; Pyrazoles; Risk Factors; Sulfonamides; Wound Healing | 2010 |
Is the sulphonamide radical in the celecoxib molecule essential for its analgesic activity?
Topics: Acetazolamide; Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Hyperalgesia; Inflammation; Male; Naltrexone; Narcotic Antagonists; Pain; Pain Measurement; Pain Threshold; Pyrazoles; Rats; Rats, Sprague-Dawley; Sulfonamides | 2010 |
Chemopreventive effects of non-steroidal anti-inflammatory drugs in early neoplasm of experimental colorectal cancer: an apoptosome study.
Topics: 1,2-Dimethylhydrazine; Aberrant Crypt Foci; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Apoptosomes; Blotting, Western; Carcinogens; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Cytochromes c; Diclofenac; Immunoenzyme Techniques; Male; Mitochondria; Pyrazoles; Rats; Rats, Sprague-Dawley; Sulfonamides | 2011 |
NSAIDs and risk of lower gastrointestinal bleeding.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Celecoxib; Colonic Diseases; Diclofenac; Gastrointestinal Hemorrhage; Humans; Lower Gastrointestinal Tract; Omeprazole; Osteoarthritis; Peptic Ulcer Hemorrhage; Pyrazoles; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Sulfonamides; Upper Gastrointestinal Tract | 2010 |
Effect of selective COX-2 inhibitor, celecoxib on adjuvant-induced arthritis model in irradiated rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Inflammation Mediators; Interleukin-1beta; Interleukin-6; Male; Oxidative Stress; Pyrazoles; Rats; Rats, Wistar; Sulfonamides; Tumor Necrosis Factor-alpha; Whole-Body Irradiation | 2010 |
Inhibitory effect of selective cyclooxygenase-2 inhibitor lumiracoxib on human organic anion transporters hOAT1 and hOAT3.
Topics: Animals; Binding, Competitive; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Estrone; Etoricoxib; Humans; Inhibitory Concentration 50; Isoxazoles; Kinetics; Lactones; Methotrexate; Oocytes; Organic Anion Transport Protein 1; Organic Anion Transporters, Sodium-Independent; p-Aminohippuric Acid; Pyrazoles; Pyridines; RNA, Complementary; Sulfonamides; Sulfones; Xenopus laevis | 2010 |
Safe administration of celecoxib to a patient with repeated episodes of nephrotic syndrome induced by NSAIDs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Humans; Male; Meloxicam; Middle Aged; Nephrotic Syndrome; Osteoarthritis, Hip; Pyrazoles; Recurrence; Remission Induction; Sulfonamides; Thiazines; Thiazoles | 2011 |
Harmful effects of NSAIDs among patients with hypertension and coronary artery disease.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure; Celecoxib; Confounding Factors, Epidemiologic; Coronary Artery Disease; Diclofenac; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Hypertension; Ibuprofen; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Myocardial Infarction; Naproxen; Odds Ratio; Proportional Hazards Models; Pyrazoles; Randomized Controlled Trials as Topic; Stroke; Sulfonamides; Verapamil | 2011 |
[Bringing evidence to practice: obstacles and barriers].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Comparative Effectiveness Research; Conflict of Interest; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Approval; Drug Industry; Evidence-Based Medicine; Germany; Humans; Ibuprofen; Peptic Ulcer; Practice Guidelines as Topic; Publication Bias; Pyrazoles; Randomized Controlled Trials as Topic; Research Design; Research Support as Topic; Sulfonamides; Translational Research, Biomedical | 2011 |
The cost-effectiveness of celecoxib vs diclofenac in the treatment of osteoarthritis in the UK; an update to the NICE model using data from the CONDOR trial.
Topics: Advisory Committees; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cost-Benefit Analysis; Cyclooxygenase 2 Inhibitors; Diclofenac; Humans; Middle Aged; Models, Economic; Osteoarthritis; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; United Kingdom | 2012 |
Activation of mitochondrial apoptosis pathways in cutaneous squamous cell carcinoma cells by diclofenac/hyaluronic acid is related to upregulation of Bad as well as downregulation of Mcl-1 and Bcl-w.
Topics: Apoptosis; Apoptosis Inducing Factor; Apoptosis Regulatory Proteins; bcl-Associated Death Protein; Carcinoma, Squamous Cell; Celecoxib; Cell Cycle Checkpoints; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Cytochromes c; Diclofenac; Dinoprostone; Down-Regulation; Humans; Hyaluronic Acid; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Skin Neoplasms; Sulfonamides; Up-Regulation | 2012 |
Characterization of nerve growth factor-induced mechanical and thermal hypersensitivity in rats.
Topics: Amines; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Behavior, Animal; Celecoxib; Cyclohexanecarboxylic Acids; Diclofenac; Dose-Response Relationship, Drug; Duloxetine Hydrochloride; Gabapentin; gamma-Aminobutyric Acid; Hyperalgesia; Male; Nerve Growth Factor; Pain Threshold; Physical Stimulation; Pyrazoles; Pyridines; Rats; Rats, Sprague-Dawley; Sulfonamides; Sulfones; Thiophenes; TRPV Cation Channels | 2013 |
Novel 3-substituted-1-aryl-5-phenyl-6-anilinopyrazolo[3,4-d]pyrimidin-4-ones: docking, synthesis and pharmacological evaluation as a potential anti-inflammatory agents.
Topics: Animals; Anti-Inflammatory Agents; Celecoxib; Diclofenac; Dose-Response Relationship, Drug; Edema; Molecular Structure; Protein Binding; Pyrazoles; Pyrimidinones; Rats; Sulfonamides | 2012 |
Cyclo-oxygenase-2 inhibitors for chemoprevention of nonmelanoma skin cancer: is there a role for these agents?
Topics: Animals; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Humans; Keratosis, Actinic; Pyrazoles; Skin Neoplasms; Sulfonamides | 2013 |
How safe is Celecoxib for Asian-Indian patients with rheumatic diseases?
Topics: Adult; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Drug Substitution; Female; Humans; Hypertension; India; Indomethacin; Male; Naproxen; Pyrazoles; Retrospective Studies; Rheumatic Diseases; Sulfonamides; Tertiary Care Centers | 2013 |
Celecoxib-loaded PLGA/cyclodextrin microspheres: characterization and evaluation of anti-inflammatory activity on human chondrocyte cultures.
Topics: Anti-Inflammatory Agents; Calorimetry, Differential Scanning; Celecoxib; Cells, Cultured; Chondrocytes; Circular Dichroism; Cyclodextrins; Diclofenac; Diffusion; Humans; Lactic Acid; Microspheres; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Pyrazoles; Sulfonamides | 2013 |
Nonsteroidal anti-inflammatory drugs diclofenac and celecoxib attenuates Wnt/β-catenin/Tcf signaling pathway in human glioblastoma cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; beta Catenin; Celecoxib; Cell Line, Tumor; Cell Movement; Cell Proliferation; Diclofenac; Glioblastoma; Humans; Pyrazoles; Sulfonamides; TCF Transcription Factors; Wnt Proteins; Wnt Signaling Pathway | 2013 |
More pain for painkillers.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Humans; Ibuprofen; Naproxen; Pain; Pyrazoles; Risk Factors; Safety-Based Drug Withdrawals; Sulfonamides; United States; United States Food and Drug Administration | 2013 |
Effects of aggregation of drug and diagnostic codes on the performance of the high-dimensional propensity score algorithm: an empirical example.
Topics: Adolescent; Adult; Aged; Algorithms; Arthritis; Celecoxib; Confounding Factors, Epidemiologic; Cyclooxygenase 2 Inhibitors; Diclofenac; Gastrointestinal Diseases; Hemorrhage; Humans; Ibuprofen; Incidence; Middle Aged; Models, Statistical; Prevalence; Propensity Score; Pyrazoles; Randomized Controlled Trials as Topic; Risk Factors; Sulfonamides; Treatment Outcome; Young Adult | 2013 |
Pharmacokinetic interactions between rebamipide and selected nonsteroidal anti-inflammatory drugs in rats.
Topics: Alanine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Proteins; Celecoxib; Diclofenac; Drug Interactions; Male; Protein Binding; Pyrazoles; Quinolones; Rats; Rats, Sprague-Dawley; Sulfonamides | 2014 |
Effects of rebamipide on nephrotoxicity associated with selected NSAIDs in rats.
Topics: Alanine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Celecoxib; Cell Adhesion Molecules; Creatinine; Diclofenac; Dinoprostone; Drug Interactions; Kidney; Kidney Diseases; Male; Nitric Oxide; Potassium; Pyrazoles; Quinolones; Rats; Rats, Sprague-Dawley; Sodium; Sulfonamides | 2013 |
Effect of vitamin B12 on functional recovery and histopathologic changes of tibial nerve-crushed rats.
Topics: Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Drug Therapy, Combination; Male; Nerve Regeneration; Neuroprotective Agents; Pyrazoles; Rats; Rats, Wistar; Sulfonamides; Tibial Nerve; Time Factors; Vitamin B 12 | 2014 |
HIV-TAT enhances the transdermal delivery of NSAID drugs from liquid crystalline mesophases.
Topics: Administration, Cutaneous; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Diclofenac; Diffusion; Digoxin; Drug Carriers; Glycerides; Liquid Crystals; Permeability; Protein Structure, Secondary; Skin; Sus scrofa; tat Gene Products, Human Immunodeficiency Virus; Viscosity; Water | 2014 |
A cost-effectiveness analysis of celecoxib compared with diclofenac in the treatment of pain in osteoarthritis (OA) within the Swedish health system using an adaptation of the NICE OA model.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cost-Benefit Analysis; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Therapy, Combination; Humans; Markov Chains; Models, Economic; Osteoarthritis; Proton Pump Inhibitors; Pyrazoles; Quality-Adjusted Life Years; Sulfonamides; Sweden | 2014 |
Potent drugs that attenuate anti-Candida albicans activity of fluconazole and their possible mechanisms of action.
Topics: Antifungal Agents; ATP-Binding Cassette Transporters; Candida albicans; Candidiasis; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Fluconazole; Fungal Proteins; Gene Expression; Ibuprofen; Membrane Transport Proteins; Microbial Sensitivity Tests; Omeprazole; Phenylpropionates; Proton Pump Inhibitors | 2014 |
How to mechanistically explain the CONDOR study data.
Topics: Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Humans; Intestinal Mucosa; Models, Molecular; Molecular Structure; Omeprazole; Osteoarthritis; Oxidative Phosphorylation; Proton Pump Inhibitors; Pyrazoles; Sulfonamides | 2015 |
Complete Freund's adjuvant-induced reduction of exploratory activity in a novel environment as an objective nociceptive endpoint for sub-acute inflammatory pain model in rats.
Topics: Adjuvants, Immunologic; Amines; Analgesics; Animals; Behavior, Animal; Celecoxib; Cyclohexanecarboxylic Acids; Diclofenac; Disease Models, Animal; Duloxetine Hydrochloride; Exploratory Behavior; Freund's Adjuvant; Gabapentin; gamma-Aminobutyric Acid; Ibuprofen; Male; Pain; Pain Measurement; Rats; Rats, Sprague-Dawley | 2015 |
Nonsteroidal anti-inflammatory drugs in-vitro and in-vivo treatment and Multidrug Resistance Protein 4 expression in human platelets.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Case-Control Studies; Celecoxib; Cells, Cultured; Cyclooxygenase 2 Inhibitors; Diclofenac; Female; Humans; Megakaryocytes; Middle Aged; Multidrug Resistance-Associated Proteins; Naproxen; Osteoarthritis; Platelet Activation; Platelet Aggregation; RNA, Messenger | 2016 |
Two-photon uncageable enzyme inhibitors bearing targeting vectors.
Topics: Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Lasers; Photons | 2015 |
Celecoxib or diclofenac hepatic status in the presence or absence of rebamipide.
Topics: Alanine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Male; Quinolones; Rats; Rats, Sprague-Dawley | 2015 |
Mitochondrial toxicity of selective COX-2 inhibitors via inhibition of oxidative phosphorylation (ATP synthesis) in rat liver mitochondria.
Topics: Adenosine Triphosphate; Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Isoxazoles; Lactones; Male; Mitochondria, Liver; Oxidative Phosphorylation; Pyridines; Rats, Sprague-Dawley; Sulfonamides; Sulfones | 2016 |
Evidence that diclofenac and celecoxib are thyroid hormone receptor beta antagonists.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Computer Simulation; Cyclooxygenase 2 Inhibitors; Diclofenac; Humans; Male; Mesenteric Arteries; Models, Molecular; Naproxen; Rats; Rats, Wistar; Thyroid Hormone Receptors beta; Triiodothyronine; Vasodilation | 2016 |
Predictive Factors for NSAIDs-related Gastrointestinal Toxicity: Can COX-2 Selective Inhibtor Prevent it?.
Topics: Adrenal Cortex Hormones; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Antineoplastic Agents; Aspirin; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Diclofenac; Duodenal Diseases; Duodenal Ulcer; Endoscopy, Digestive System; Etodolac; Female; Humans; Logistic Models; Male; Middle Aged; Phenylpropionates; Protective Factors; Proton Pump Inhibitors; Retrospective Studies; Risk Factors; Stomach Diseases; Stomach Ulcer | 2015 |
Expression of Endoglin and Vascular Endothelial Growth Factor as Prognostic Markers in Experimental Colorectal Cancer.
Topics: Adenocarcinoma; Animals; Biomarkers, Tumor; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Diclofenac; Endoglin; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Inflammation; Neoplasms, Experimental; Neovascularization, Pathologic; Prognosis; Rats; Transforming Growth Factor beta1; Vascular Endothelial Growth Factor A | 2016 |
(1)H-Nuclear magnetic resonance-based metabolic profiling of nonsteroidal anti-inflammatory drug-induced adverse effects in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug-Related Side Effects and Adverse Reactions; Gastric Mucosa; Ibuprofen; Indomethacin; Least-Squares Analysis; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Metabolomics; Piroxicam; Rats; Rats, Sprague-Dawley | 2016 |
Chemoprevention of Colon Cancer through Inhibition of Angiogenesis and Induction of Apoptosis by Nonsteroidal Anti-Inflammatory Drugs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Apoptosis; Celecoxib; Colonic Neoplasms; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Female; Neovascularization, Pathologic; Pyridines; Rats; Rats, Sprague-Dawley; Sulfones | 2016 |
Inhibition of Aβ(1-42)Oligomerization, Fibrillization and Acetylcholinesterase Activity by Some Anti-Inflammatory Drugs: An in vitro Study.
Topics: Acetylcholinesterase; Amyloid; Amyloid beta-Peptides; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Aspirin; Butylated Hydroxyanisole; Celecoxib; Dexamethasone; Diclofenac; Indomethacin; Methylene Blue; Nitric Oxide; Peptide Fragments; Piroxicam; Rivastigmine; Singlet Oxygen | 2017 |
Hyperalgesic and hypoalgesic mechanisms evoked by the acute administration of CCL5 in mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chemokine CCL5; Cyclooxygenase 2 Inhibitors; Diclofenac; Hyperalgesia; Male; Mice; Pain Measurement; Pain Threshold; Receptors, CCR1; Receptors, CCR5 | 2017 |
Aryl/heteroaryl Substituted Celecoxib Derivatives as COX-2 Inhibitors: Synthesis, Anti-inflammatory Activity and Molecular Docking Studies.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Female; Flufenamic Acid; Male; Molecular Docking Simulation; Rats, Wistar | 2017 |
Nonsteroidal anti-inflammatory drugs-induced failure of lower esophageal and pyloric sphincter and counteraction of sphincters failure with stable gatric pentadecapeptide BPC 157 in rats.
Topics: Acetaminophen; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Celecoxib; Diclofenac; Esophageal Sphincter, Lower; Ibuprofen; Male; Peptide Fragments; Pressure; Proteins; Pylorus; Rats, Wistar | 2017 |
Role of GSK-3β in Regulation of Canonical Wnt/β-catenin Signaling and PI3-K/Akt Oncogenic Pathway in Colon Cancer.
Topics: 1,2-Dimethylhydrazine; Animals; Anticarcinogenic Agents; Apoptosis; Celecoxib; Cell Transformation, Neoplastic; Colon; Colonic Neoplasms; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Female; Glycogen Synthase Kinase 3 beta; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyridines; Rats, Sprague-Dawley; Sulfones; Time Factors; Wnt Signaling Pathway | 2017 |
NSAIDs relieve osteoarthritis (OA) pain, but cardiovascular safety in question even for diclofenac, ibuprofen, naproxen, and celecoxib: what are the alternatives?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Diclofenac; Humans; Ibuprofen; Naproxen; Network Meta-Analysis; Osteoarthritis; Pain | 2017 |
Diclofenac but not celecoxib improves endothelial function in rheumatoid arthritis: A study in adjuvant-induced arthritis.
Topics: Animals; Aorta, Thoracic; Arginase; Arginine; Arthritis, Experimental; Biological Factors; Blood Pressure; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Endothelium, Vascular; Freund's Adjuvant; In Vitro Techniques; Male; NADPH Oxidases; Nitric Oxide Synthase Type III; Phosphorylation; Rats, Inbred Lew; Vasodilation; Vasodilator Agents | 2017 |
Penetration and pharmacokinetics of non-steroidal anti-inflammatory drugs in rat prostate tissue.
Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Celecoxib; Chromatography, Liquid; Comparative Effectiveness Research; Diclofenac; Disease Models, Animal; Ibuprofen; Inflammation; Male; Naproxen; Pelvic Pain; Prostate; Prostatitis; Rats; Rats, Sprague-Dawley; Tissue Distribution | 2018 |
Efficacy and safety of combined low doses of either diclofenac or celecoxib with gabapentin versus their single high dose in treatment of neuropathic pain in rats.
Topics: Amines; Analgesics; Animals; Behavior, Animal; Celecoxib; Cyclohexanecarboxylic Acids; Diclofenac; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Gabapentin; gamma-Aminobutyric Acid; Male; Neuralgia; Oxidative Stress; Pain Measurement; Pain Threshold; Rats, Wistar; Treatment Outcome | 2018 |
Comparative cardiovascular safety of nonsteroidal anti-inflammatory drugs in patients with hypertension: a population-based cohort study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular System; Celecoxib; Cyclooxygenase 2 Inhibitors; Databases, Pharmaceutical; Diclofenac; Female; Hospitalization; Humans; Hypertension; Ibuprofen; Male; Mefenamic Acid; Middle Aged; Naproxen; Risk Factors | 2018 |
Effect on Risk of Stroke and Acute Myocardial Infarction of Nonselective Nonsteroidal Anti-Inflammatory Drugs in Patients With Rheumatoid Arthritis.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Diclofenac; Female; Humans; Ibuprofen; Logistic Models; Male; Mefenamic Acid; Meloxicam; Middle Aged; Myocardial Infarction; Odds Ratio; Risk Factors; Stroke | 2018 |
The effectiveness of cyclooxygenase-2 inhibitors and evaluation of angiogenesis in the model of experimental colorectal cancer.
Topics: 1,2-Dimethylhydrazine; Animals; Apoptosis; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Diclofenac; Intestinal Mucosa; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neovascularization, Pathologic; Rats, Sprague-Dawley; Tissue Inhibitor of Metalloproteinase-2 | 2018 |
Copaiba oil enhances in vitro/in vivo cutaneous permeability and in vivo anti-inflammatory effect of celecoxib.
Topics: Animals; Anti-Inflammatory Agents; Celecoxib; Diclofenac; Diethylamines; Drug Synergism; Edema; Fabaceae; Male; Mice; Oils, Volatile; Skin Absorption; Swine | 2018 |
Design, synthesis and evaluation of some pyrazolo[3,4-d]pyrimidine derivatives bearing thiazolidinone moiety as anti-inflammatory agents.
Topics: Animals; Anti-Inflammatory Agents; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Drug Design; Edema; Female; Granuloma; Pyrazoles; Pyrimidines; Rats; Rats, Wistar; Structure-Activity Relationship; Thiazolidines | 2018 |
Comparative safety of NSAIDs for gastrointestinal events in Asia-Pacific populations: A multi-database, international cohort study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Australia; Celecoxib; Databases, Factual; Diclofenac; Female; Follow-Up Studies; Gastrointestinal Diseases; Hong Kong; Hospitalization; Humans; Incidence; Japan; Male; Mefenamic Acid; Phenylpropionates; Republic of Korea; Taiwan | 2018 |
Factors affecting the results of analgesic therapy. Results of the Russian multicentre study of NOTE (NSAID: Open-label Trial of Efficacy).
Topics: Adult; Aged; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Diclofenac; Female; Humans; Male; Middle Aged; Pain; Russia | 2018 |
Synthesis, modeling and biological evaluation of some pyrazolo[3,4-d]pyrimidinones and pyrazolo[4,3-e][1,2,4]triazolo[4,3-a]pyrimidinones as anti-inflammatory agents.
Topics: Animals; Anti-Inflammatory Agents; Binding Sites; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Edema; Female; Granuloma; Inflammation; Molecular Docking Simulation; Molecular Structure; Pyrazoles; Pyrimidinones; Rats, Wistar; Structure-Activity Relationship; Triazoles | 2019 |
Mitochondrial Permeability Transition Pore Sealing Agents and Antioxidants Protect Oxidative Stress and Mitochondrial Dysfunction Induced by Naproxen, Diclofenac and Celecoxib.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Apoptosis; Celecoxib; Diclofenac; Glutathione; Lipid Peroxidation; Male; Mitochondria; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Myocytes, Cardiac; Naproxen; Oxidative Stress; Protective Agents; Rats; Rats, Wistar; Reactive Oxygen Species | 2019 |
Liquid chromatographic method for simultaneous determination of alprazolam with NSAIDs in bulk drug, pharmaceutical formulation and human serum.
Topics: Alprazolam; Celecoxib; Chromatography, High Pressure Liquid; Diclofenac; Humans; Limit of Detection; Tablets | 2020 |
Celecoxib vs diclofenac sodium in patients with knee osteoarthritis: A protocol for systematic review and meta analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Sedimentation; C-Reactive Protein; Celecoxib; Diclofenac; Female; Humans; Male; Meta-Analysis as Topic; Osteoarthritis, Knee; Quality Assurance, Health Care; Randomized Controlled Trials as Topic; Systematic Reviews as Topic; Treatment Outcome; Visual Analog Scale | 2020 |
Letter to the Editor Regarding a Recent Article: Meta-Analysis Comparing Celecoxib with Diclofenac Sodium in Patients with Knee Osteoarthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Diclofenac; Humans; Osteoarthritis, Knee | 2022 |
Non-ulcerogenic pyrazolyl 2-hydroxychalcones and pyrazolylpyrazolines derived from naturally existing furochromone (khellin): semi-synthesis, docking study and anti-inflammatory activity.
Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Edema; Khellin; Molecular Docking Simulation; Molecular Structure; Rats; Structure-Activity Relationship | 2022 |
The effective interplay of (non-) selective NSAIDs with neostigmine in animal models of analgesia and inflammation.
Topics: Acetic Acid; Analgesia; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Diclofenac; Disease Models, Animal; Drug Interactions; Drug Therapy, Combination; Edema; Female; Formaldehyde; Neostigmine; Pain; Rats, Sprague-Dawley | 2021 |
Montelukast potentiates the antiinflammatory effect of NSAIDs in the rat paw formalin model and simultaneously minimizes the risk of gastric damage.
Topics: Acetates; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclopropanes; Diclofenac; Formaldehyde; Inflammation; Male; Nitric Oxide Synthase Type II; Quinolines; Rats; Rats, Wistar; Risk; Signal Transduction; Stomach; Sulfides | 2021 |
Non-steroidal anti-inflammatory drugs in the elderly. Agreement with safe prescription recommendations according to cardiovascular and gastrointestinal risks.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Diclofenac; Humans; Pharmaceutical Preparations; Prescriptions | 2021 |
Association between tramadol use and risk of pneumonia in the middle-aged and elderly populations: a propensity-score matched cohort study.
Topics: Aged; Analgesics; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Codeine; Cohort Studies; Diclofenac; Etoricoxib; Humans; Middle Aged; Naproxen; Pneumonia; Tramadol | 2022 |
Effects of Different Nonsteroidal Anti-Inflammatory Drugs Combined with Platelet-Rich Plasma on Inflammatory Factor Levels in Patients with Osteoarthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Diclofenac; Humans; Osteoarthritis, Knee; Platelet-Rich Plasma; Retrospective Studies; Treatment Outcome | 2022 |
A comprehensive update on the pharmacological management of heterotopic ossification following hip arthroplasty: a level I evidenced based expert opinion.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthroplasty, Replacement, Hip; Celecoxib; Diclofenac; Expert Testimony; Humans; Naproxen; Ossification, Heterotopic; Postoperative Complications | 2022 |
Cardiovascular Risks of Diclofenac Versus Other Older COX-2 Inhibitors (Meloxicam and Etodolac) and Newer COX-2 Inhibitors (Celecoxib and Etoricoxib): A Series of Nationwide Emulated Trials.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Etodolac; Etoricoxib; Female; Heart Disease Risk Factors; Humans; Meloxicam; Risk Factors | 2022 |
NSAIDs affect dendritic cell cytokine production.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antigens, Neoplasm; CD8-Positive T-Lymphocytes; Celecoxib; Cytokines; Dendritic Cells; Diclofenac; Humans; Ibuprofen; Mice; Neoplasms | 2022 |
Gestational NSAIDs distinctly reprogram cardiac injury in preeclamptic rats: Roles of cyclooxygenase, apoptotic and autophagic trails.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Female; Humans; Naproxen; Placenta; Pre-Eclampsia; Pregnancy; Rats | 2022 |
Triple targeting of mutant EGFR
Topics: Anti-Inflammatory Agents; Celecoxib; Cyclooxygenase 2; Diclofenac; ErbB Receptors; Humans; Lung Neoplasms; Molecular Docking Simulation; Mutation; Protein Kinase Inhibitors; Quinazolinones; Structure-Activity Relationship; Tumor Necrosis Factor-alpha; Urea | 2023 |
Plasma and Hepatic Exposures of Celecoxib and Diclofenac Prescribed Alone in Patients with Cytochrome P450 2C9*3 Modeled after Virtual Oral Administrations and Likely Associated with Adverse Drug Events Reported in a Japanese Database.
Topics: Administration, Oral; Celecoxib; Cytochrome P-450 CYP2C9; Cytochrome P-450 Enzyme System; Diclofenac; Drug-Related Side Effects and Adverse Reactions; Humans; Japan | 2023 |
Synthesis of new multitarget-directed ligands containing thienopyrimidine nucleus for inhibition of 15-lipoxygenase, cyclooxygenases, and pro-inflammatory cytokines.
Topics: Anti-Inflammatory Agents; Arachidonate 15-Lipoxygenase; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cytokines; Diclofenac; Interleukin-6; Lipoxygenase Inhibitors; Molecular Docking Simulation; Pyrimidines; Reactive Oxygen Species; Structure-Activity Relationship; Tumor Necrosis Factor-alpha | 2023 |
The suppression of MAPK/NOX/MMP signaling prompts renoprotection conferred by prenatal naproxen in weaning preeclamptic rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Diclofenac; Female; Humans; Naproxen; Pre-Eclampsia; Pregnancy; Rats; Vitamins; Weaning | 2023 |